




(86) Date de dépôt PCT/PCT Filing Date: 2010/10/18
 (87) Date publication PCT/PCT Publication Date: 2011/04/28
 (85) Entrée phase nationale/National Entry: 2012/04/11
 (86) N° demande PCT/PCT Application No.: EP 2010/065589
 (87) N° publication PCT/PCT Publication No.: 2011/048033
 (30) Priorités/Priorities: 2009/10/19 (US61/253,020);
 2009/11/25 (EP09177111.3)

(51) Cl.Int./Int.Cl. *A61K 31/56* (2006.01),
A61P 9/00 (2006.01)
 (71) Demandeur/Applicant:
 ROSTAQUO S.P.A., IT
 (72) Inventeurs/Inventors:
 BIANCHI, GIUSEPPE, IT;
 FERRARI, PATRIZIA, IT;
 MACCIARDI, FABIO, IT
 (74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : PROCÉDES ET SYSTÈMES DE TRAITEMENT PHARMACOGÉNOMIQUE DE CONDITIONS
 CARDIOVASCULAIRES
 (54) Title: METHODS AND SYSTEMS FOR PHARMACOGENOMIC TREATMENT OF CARDIOVASCULAR
 CONDITIONS

(57) **Abrégé/Abstract:**

Methods and systems are provided herein that are based on the effects of genetic variations on the biological activities associated to rofemfiroxin in an individual. In particular, compositions, methods and systems are herein described that are based on an identified influence on an individual response to rofemfiroxin of one or more polymorphisms in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and/or a genetic variation in linkage disequilibrium therewith.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 April 2011 (28.04.2011)(10) International Publication Number
WO 2011/048033 A3

(51) International Patent Classification:

A61K 31/56 (2006.01) *A61P 9/00* (2006.01)

(21) International Application Number:

PCT/EP2010/065589

(22) International Filing Date:

18 October 2010 (18.10.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/253,020 19 October 2009 (19.10.2009) US
09177111.3 25 November 2009 (25.11.2009) EP(71) Applicant (for all designated States except US): **ROSTAUQUO S.p.A.** [IT/IT]; Via Pontina, km 30,400, I-00040 Pomezia (RM) (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BIANCHI, Giuseppe** [IT/IT]; Piazza Adigrat, 4, I-20133 Milano (IT). **FERRARI, Patrizia** [IT/IT]; Via Gasparotto, 57/A, I-21100 Varese (IT). **MACCIARDI, Fabio** [IT/IT]; Via Disciplini, 18, I-20123 Milano (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

14 July 2011

(54) Title: METHODS AND SYSTEMS FOR PHARMACOGENOMIC TREATMENT OF CARDIOVASCULAR CONDITIONS

(57) Abstract: Methods and systems are provided herein that are based on the effects of genetic variations on the biological activities associated to rofustafuroxin in an individual. In particular, compositions, methods and systems are herein described that are based on an identified influence on an individual response to rofustafuroxin of one or more polymorphisms in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and/or a genetic variation in linkage disequilibrium therewith.



WO 2011/048033 A3

**METHODS AND SYSTEMS FOR PHARMACOGENOMIC TREATMENT OF
CARDIOVASCULAR CONDITIONS**

CROSS REFERENCE TO RELATED APPLICATIONS

The present disclosure is related and claims priority to US provisional
5 Application S/N 61/253,020 entitled "Methods and Systems for
Pharmacogenomic Treatment of CardioVascular Conditions" filed on
October 19, 2009 and to EP application S/N 09177111.3 entitled "Methods
and Systems for Pharmacogenomic Treatment of CardioVascular
Conditions" filed on November 25, 2009, the disclosure of each of which is
10 herein incorporated by reference in its entirety.

FIELD

The present disclosure relates to a class of compounds formed by 17β -(3-furyl)- 5β -
androstane- 3β , 14β , 17α -triol, and derivatives thereof, herein collectively indicated
as rostafuroxin.

15 BACKGROUND

Rostafuroxin is a compound known to have a biological activity in individuals. In
particular, rostafuroxin has been shown to be active on the cardiovascular system
of individuals and is under development for the treatment of cardiovascular
disorders, such as arterial hypertension and related organ complications, including
20 but not limited to cardiac failure, coronary heart disease (CHD) stroke and renal
failure.

More particularly, rostafuroxin has been shown to be a compound that normalizes blood pressure and alterations in the Na-K pump and Src caused by, but not only, either ouabain or genetic variations in genes coding for the cytoskeletal adducin such as ADD1, ADD2, ADD3.

5 Additionally, rostafuroxin has been shown to be capable of normalizing the alterations of the podocyte proteins causing excessive proteinuria, glomerulosclerosis and renal failure and antagonizing the biological processes (neointima formation and negative remodeling) causing arterial stenosis after arteriotomy and angioplasty.

10 SUMMARY

Provided herein are methods and systems that, allow, in several embodiments, therapeutic and/or analytical uses of rostafuroxin based on the influence of genetic variations on an individual's responses to rostafuroxin.

In particular, compositions, methods and systems are herein described that are
15 based on an identified influence on an individual response to rostafuroxin of one or more polymorphisms in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and/or a genetic variation in linkage disequilibrium therewith. Said regions were not previously known to be correlated in any way to a cardiovascular condition, genetic
20 predisposition or drug response in humans.

More particularly, compositions, methods and systems herein described are based on the identified influence on an individual response to rostafuroxin of one or more

polymorphisms selected from the groups consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375 (herein also called core SNPs), and/or a genetic variation in linkage disequilibrium therewith.

According to a first aspect, rostavuroxin for use in treatment or prevention of a cardiovascular condition in an individual is described, wherein the individual has been selected to be a carrier of at least one polymorphism selected from the groups consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375, and/or a genetic variation in linkage disequilibrium therewith. In an embodiment, a method for treating or preventing a cardiovascular condition in an individual is described. The method comprises administering or prescribing rostavuroxin to said individual, wherein said individual has been determined to be a carrier of at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375, and/or a genetic variation in linkage disequilibrium therewith.

According to a second aspect, rostavuroxin for use as a medicament in a dosage of in a dosage of from 0.005 mg/day to 5 mg/day is described. In particular, the use of rostavuroxin in a dosage of from 0.005 mg/day to 5 mg/day is described for treating an individual wherein the individual has been selected to have a genotype comprising at least one of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375 and/or a genetic variation in linkage disequilibrium therewith. In particular, in an embodiment a method for treating an individual with rostavuroxin is described. The method comprises: administering or prescribing

rostafuroxin to the individual in a dosage of from 0.05 mg/day to 5 mg/day, and in particular 0.05 mg/day to 0.5 mg/day, wherein the individual has been determined to have a genotype comprising at least one of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375, and/or a genetic variation in linkage disequilibrium therewith.

According to a third aspect, a method and system for evaluating a therapy with rostafuroxin for an individual are disclosed. The method comprises detecting in the individual sequence information for at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375, and/or a genetic variation in linkage disequilibrium therewith; and determining the therapy with rostafuroxin in the individual based on the detected sequence information. In particular, the sequence information can be detected from an isolated DNA sample of the individual or in other isolated samples of the individual suitable to provide sequence information. The system comprises a probe for at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375, and/or a genetic variation in linkage disequilibrium therewith; and a pharmaceutical composition comprising rostafuroxin in a dosage of from 0.005 mg to 5 mg/kg and in particular 0.005 mg/day to 0.5 mg/day, and a pharmaceutically acceptable vehicle.

According to a fourth aspect, a method and system for predicting a response to rostafuroxin in an individual are disclosed. The method comprises: detecting a

genotype in the individual for an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and comparing the detected genotype with previously identified genotypes associated with a known response to rostaduroxin, the previously identified

5 genotypes comprising at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375. The system comprises a probe for at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375 and a look-up table associating results of

10 probes hybridization and previously identified genotypes. In particular, detecting the genotype can be performed from an isolated DNA sample of the individual or in other isolated samples of the individual suitable to provide information on the genotype. In the method and system, if the genotype identified in the individual is the same genotype associated with the rostaduroxin response, the response of the

15 individual to rostaduroxin is predicted to be the known response.

According to a fifth aspect, a method and system for detecting a single nucleotide polymorphism (SNP) in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29 are disclosed. In particular, detecting the genotype can be performed from

20 an isolated DNA sample of the individual or in other isolated samples of the individual suitable to provide information on the genotype. The system comprises an isolated polynucleotide which specifically hybridizes to a nucleic acid molecule

containing a single nucleotide polymorphism (SNP) in any one of the nucleotide sequences SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID NO: 11, a buffer, and an enzyme. The method comprises contacting genomic fragments comprising intergenic or intragenic regions of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29 with a single base specific probe for at least one of the nucleotide sequences from SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID NO:11 or a portion thereof. In particular, the contacting can be performed on isolated genomic fragment of the individual or in other isolated samples of the individual suitable to provide information on genomic fragments.

According to a sixth aspect, an isolated nucleic acid molecule comprising at least about 100 contiguous nucleotides wherein one of the nucleotides is a single nucleotide polymorphism (SNP) selected from any one of the nucleotide sequences in SEQ ID NO:2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, and SEQ ID NO: 12, or a complement thereof.

According to a seventh aspect, a method and system for identifying an agent useful in therapeutically or prophylactically treating a cardiovascular condition are disclosed.

The method comprises providing a candidate agent; administering the candidate agent to an individual carrying at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and

rs12513375, and/or a genetic variation in linkage disequilibrium therewith; and detecting the individual response to said candidate agent.

The methods and systems herein described allow in several embodiments increasing the rate of success of the therapy for a cardiovascular condition, in particular for hypertension, from the present 30-40% to about 80%.

The methods and systems herein described in several embodiments allow increasing a rate of success of the therapy for a cardiovascular condition, in particular for hypertension, in never treated individuals.

The methods and systems herein described can be used in several embodiments to reduce the rate of adverse events and side effects as compared with the available therapies by selecting the responder individuals and reducing the effective dosages and as consequence of the possible unwanted side effects.

The methods and systems herein described can be applied in connection with any application, such as medical, diagnostic, cosmetic and pharmacological applications associated with any activity of rostafuroxin in an individual.

The details of one or more embodiments of the disclosure are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.

20 BRIEF DESCRIPTION OF THE FIGURES

The accompanying drawings, which are incorporated into and constitute a part of this specification, illustrate one or more embodiments of the present disclosure

and, together with the detailed description and examples, serve to explain the principles and implementations of the disclosure.

Figure 1 shows a Gaussian distribution detected in connection with a genetic descriptive analysis performed on individuals treated with rostafuroxin and placebo.

5 In particular, **Panel A** shows a diagram illustrating the distribution of blood pressure changes (DSBP5_0) in individuals after 5 weeks of treatment with rostafuroxin and placebo or both (all patients). **Panel B** shows a diagram illustrating the distribution of blood pressure changes (DSBP5_0) in individuals after 5 weeks of treatment with rostafuroxin (rostafuroxin). **Panel C** shows a
10 diagram illustrating the distribution of blood pressure changes (DSBP5_0) in individuals after 5 weeks of treatment with placebo (Placebo).

Figure 2 shows a Gaussian distribution detected in connection with a genetic descriptive analysis performed on individuals treated with rostafuroxin. In particular

Figure 2 shows a diagram illustration the distribution of blood pressure changes
15 (DSBP5_0) after 5 weeks of treatment with rostafuroxin shown in Figure 1B subdivided in tertiles.

Figure 3 shows results statistical analysis performed in connection with a genetic descriptive analysis performed on individuals treated with rostafuroxin. In particular, **Figure 3** shows the top two axis of variation of Principal Component
20 Analysis (PCA1 and PCA2) of Eigensoft for 193 patients to illustrate the genetic relatedness among individuals. Each point represents an individual. In the plot, a

mild heterogeneous clusterization of individuals distributed around zero is detectable.

Figure 4 shows a diagram illustrating the results of GXE association results for placebo and therapy of SNPs according to some embodiments herein disclosed. In

5 **Panel A**, the Y axis of the plot represents the pvalue of significance ($-\log P$ value) while the X axis the position in the genome. Each point represents a SNP and in particular the red dots represent SNPs with a significant pvalue ($p < 10^{-4}$). **Panel B** shows comparison of distributions of observed versus expected pvalues generated by GXT association Test (Q-Q plot). The inflation in the tail of the distribution
10 represents true positive associations.

Figure 5 shows diagrams illustrating steps for selection of genotypes of interactions of SNPs for rostaduroxin according to some embodiments of the present disclosure. In particular, **Figure 5** shows diagrams each reporting the interaction between different genotypes of rs8899 and rs4678 with respect to blood
15 pressure changes (DSBP5_0) in individuals treated with rostaduroxin and placebo as indicated.

Figure 6 shows an exemplary univariate analysis performed to select genotypes affecting response to rostaduroxin according to some embodiments herein disclosed.

20 **Figure 7** shows a diagram illustrating an exemplary interaction between different genotypes of one hypothetical SNP and the blood pressure changes (DSBP5_0) with rostaduroxin and placebo.

Figure 8 shows a summary of exemplary data related to genetic profiles according to some embodiments herein described.

Figure 9 shows a summary of selected genes related to the vascular, renal and nervous modulation of blood pressure according to some embodiments herein
5 described.

Figure 10 shows data concerning the efficacy and safety of traditional and pharmacogenomic approaches.

DETAILED DESCRIPTION

Methods and systems are provided herein that are based on the effects of genetic
10 variations on the biological activity associated to rostaduroxin in an individual.


In particular, methods and systems herein provided are based on polymorphisms in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and/or a genetic variation in linkage disequilibrium therewith.

15 More particularly, compositions, methods and systems herein described are based on the identified influence on an individual response to rostaduroxin of one or more polymorphisms selected from the groups consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375, and/or a genetic variation in linkage disequilibrium therewith.

20 The wording “genetic variation” or “polymorphism” as used herein indicates genetic diversity in a population of individuals and in particular is an altered state of a region of DNA or chromosome. Exemplary polymorphisms comprise VNTR





(variable number of tandem repeats, also known as minisatellite and microsatellite), base pairs substitutions, base pairs insertion, base pairs deletion, changes in karyotype (aneuploidy, polyploidy) and chromosome rearrangements (deletion, translocation, inversion).

- 5 The term “rostafuroxin” as used herein indicates any one of the compounds of a class formed by 17β -(3-furyl)- 5β -androstane- $3\beta,14\beta,17\alpha$ -triol, and derivatives thereof. More particularly, the rostafuroxin compounds comprise compounds of formula I.



10

(I)

wherein: the symbol  means that the substituents in position 17 can have an α or β configuration; the symbol  represents a single or a double bond; Y is oxygen or guanidinoimino, when  in position 3 is a double bond; Y is hydroxy, OR^4 or SR^4 , when  in position 3 is a single bond and can have an α or β configuration;

R is an unsubstituted or substituted 3-furyl or 4-pyridazinyl group;

R¹ is hydrogen; methyl; ethyl or *n*-propyl substituted by OH or NR⁵R⁶;

R² is hydrogen or together to R³ is a bond of an oxirane ring;

R³ is hydrogen or together to R² is a bond of an oxirane ring;

R⁴ is hydrogen; methyl; C2-C6 alkyl or C3-C6 alkenyl or C2-C6 acyl, these
5 alkyl, alkenyl and acyl groups being unsubstituted or substituted by a quaternary
ammonium group or one or more OR⁷, NR⁸R⁹, formyl, amidino, guanidinoimino or
by NR⁸R⁹ and hydroxy;

R⁵, R⁶ are independently hydrogen; methyl; C2-C6 alkyl unsubstituted or
substituted by one NR¹⁰R¹¹, or NR¹⁰R¹¹ and hydroxy, or R⁵ and R⁶ taken
10 together with the nitrogen atom form an unsubstituted or substituted saturated or
unsaturated penta- or hexa-monoheterocyclic ring, optionally containing another
heteroatom chosen from oxygen or sulfur or nitrogen;

R⁷ is hydrogen, methyl or C2-C4 alkyl, this alkyl being unsubstituted or
substituted by one or more NR¹⁰R¹¹ or by NR¹⁰R¹¹ and hydroxy;

15 R⁸, R⁹ are independently hydrogen; methyl; C2-C6 alkyl or C3-C6 alkenyl,
these alkyl and alkenyl groups being unsubstituted or substituted by one or more
NR¹⁰R¹¹, or NR¹⁰R¹¹ and hydroxy, or R⁸ and R⁹ taken together with the
nitrogen atom form an unsubstituted or substituted saturated or unsaturated penta-
or hexa-monoheterocyclic ring, optionally containing another heteroatom chosen
20 from oxygen or sulfur or nitrogen, or R⁸ is hydrogen and R⁹ is amidino;

R¹⁰, R¹¹ are independently hydrogen, C1-C6 alkyl, or R¹⁰ and R¹¹, taken together with the nitrogen atom form a saturated or unsaturated penta- or hexa-monoheterocyclic ring.

In particular, the term rostafuroxin as used herein includes all the possible stereoisomers, in particular Z and E isomers, optical isomers and their mixtures as well as metabolites and the metabolic precursors of the compounds of formula (I). The term “derivative” as used herein indicates a chemically modified compound of formula (I) which retains at least one of the biological activities associated with the compound of Formula (I). Chemical modifications can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group and additional modifications identifiable by a skilled person.

Reference is also made to US patent 5,591,734, Bianchi al., 2003, and Quadri et al 1997 [Ref. 4, 5] and the related supporting information, (each incorporated herein by reference in its entirety) which describe the synthesis and biological activity of rostafuroxin compounds.

Additional biological activities associated to rostafuroxin are described in Ferrari P. et al., 1998 [Ref. 6], also incorporated herein by reference in its entirety.

The wording “biological activity” as used herein with reference to rostafuroxin indicates the quality or state of any effects of rostafuroxin, or relating to rostafuroxin on a living matter. Biological activities of rostafuroxin include but are not limited to selective inhibition of the ouabain hypertensive effect, normalization of alterations in the Na-K pump and Src caused by ouabain, and normalization in

forms of hypertension sustained by the concomitant increase of endogenous ouabain levels and alterations in the Na-K pump and Src. In particular, biological activities of rostafuroxin comprise a selective antagonism of the hypertensive effect associated to the genetic variations of genes coding for adducin or other enzymes involved in synthesis and transport of endogenous ouabain, normalization of alterations in the Na-K pump and Src caused by adducin genetic variations [Ref. 1, 2, 3], and normalization in forms of hypertension sustained by the concomitant effects of adducin genetic variations and alterations in the Na-K pump and Src. Biological activities of rostafuroxin also include but are not limited to the normalization of the alterations of the podocyte proteins causing excessive proteinuria, glomerulosclerosis and renal failure and antagonism of the biological processes causing arterial stenosis after arteriotomy and angioplasty and additional activities identifiable by a skilled person upon reading of the present disclosure.

As described in the present disclosure, the biological activities associated with rostafuroxin are affected by genetic variations in individuals so that in several embodiments the treatment with rostafuroxin results in an enhanced biological activity compared to the biological activity elicited in individuals not presenting the genetic variations.

Additionally, since rostafuroxin activity is dosage-dependent, methods and systems herein described allow in several embodiments effective administration of

rostafuroxin to the individuals carrying the genetic variations with corresponding decrease of possible side effects.

The detectable biological activities associated with rostafuroxin in an individual define the response of the individual to rostafuroxin. The biological activities can be
5 detected with methods and techniques identifiable by a skilled person, which include but are not limited to detection of biomarkers associated with the biological activity, and detection of a vital signs and other clinical information associated to the biological activity in the individual with particular reference to the blood pressure of the individual.

10 In several embodiments of the present disclosure administration of rostafuroxin to an individual carrying a genetic variation according to the present disclosure results in an improved response to rostafuroxin in the individual.

In particular an “improved response” in the sense of the present description indicates the enhanced activities of rostafuroxin as detected in the individual, which
15 in several embodiments comprise at least one of prevention of hypertension, reduction of blood pressure, normalization of blood pressure, and prevention of the cardiovascular, renal, vascular, ocular and nervous damages or complications associated to hypertension. In particular, an improved response can be defined, in
20 several embodiments, by an average office systolic blood pressure decrease from about 23 mmHg to about 12 mmHg compared to blood pressure measured in the individual prior to starting the treatment.

In several embodiments an improved response can be defined by an average decrease of the office systolic blood pressure and/or nightly blood pressure of the individuals of at least about 15 and about 9 mmHg, respectively compared to blood pressure measured in the individual prior to starting the treatment. Also in several
5 embodiments an improved response can be defined by an average decrease in the office systolic blood pressure and/or nightly blood pressure at least one of the office systolic blood pressure decrease that is significantly greater (e.g. 40% or more higher) than a corresponding average decrease detected in the individual following administration of other antihypertensive such as Hydrochlorothiazide
10 (HCTZ) or Losartan.

The term “average decrease” or “average drop” as used herein with reference to blood pressure indicates a decrease that is a measure of the middle or expected value of a set of blood pressure measurements performed on an individual in a predetermined amount of time determined according to medical guidelines in view
15 of the blood pressure to be detected (e.g. nightly or office blood pressure). The specific timing of the measurements and the descriptive statistics that can be used as a measurement of the central tendency of the blood pressure measurements to calculate the average decrease are identifiable by a skilled person upon reading of the present disclosure.

20 The term “office blood pressure” as used herein indicates the blood pressure level measured by the physician in his ambulatory by suitable equipment such as a

sphygmomanometer, an electronic BP recorder or additional equipment identifiable by a skilled person.

The term “nightly blood pressure” as used here indicates the blood pressure levels recorded nightly typically from 12 p.m. to 6 a.m. by suitable equipment, such as an
5 electronic blood pressure recorder in particular according to Holter’s method) or additional equipment identifiable by a skilled person.

The term “hydrochlorothiazide” as used herein indicates a first line diuretic drug of the thiazide class that acts by inhibiting the kidneys' ability to retain water and has formula 6-chloro-1,1-dioxo-3,4-dihydro-2*H*-1,2,4-benzothiadiazine-7-sulfonamide.

10 The term “losartan” as used herein indicates an angiotensin II receptor antagonist drug used mainly to treat high blood pressure having formula (2-butyl-4-chloro-1-
{[2'-(1*H*-tetrazol-5-yl)biphenyl-4-yl]methyl}-1*H*-imidazol-5-yl)methanol.

According to the present disclosure the response of an individual to rosfafuroxin is affected by certain genetic variations and in particular by single nucleotide
15 polymorphisms that are detectable in the individual’s genotype. The term “single nucleotide polymorphism” or “SNP” as used herein indicates a genetic variation formed by single base pair substitution also called a point mutation. According to the present disclosure, SNPs or point mutations can be located in an intragenic region of a gene (e.g. in intronic or exonic regions of the gene) or intergenic
20 regions flanking a gene, and that are typically composed of genomic regions with regulatory functions or with unknown function.

The term “individuals” as used herein indicates a single biological organism such as higher animals and in particular vertebrates such as mammals and more particularly human beings.

The term “genotype” as used herein indicates the combination of alleles located on
5 homologous chromosomes for each of the genetic variations considered. In particular, in the present disclosure genotype 1 (g1) for a specific gene or position indicates the association to the homozygous less frequent genotype for that specific gene or position, genotype (g2) for a specific gene or position indicates the association to the heterozygous genotype for that specific gene or position, and
10 genotype 3 (g3) for a specific gene or position indicates association to the homozygous more frequent genotype for that specific gene or position.

In several embodiments, the genetic variations affecting rostaduroxin activities in an individual comprise at least one SNP selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375
15 (herein also indicated as “core SNPs”) and/or a genetic variation in linkage disequilibrium therewith. The core SNPs as well as other SNPs are herein often indicated using the dbSNP rsID identifiers established by the National Center for Biotechnology Information (NCBI) and available for example at <http://www.ncbi.nlm.nih.gov/projects/SNP/> at the date of filing of the present
20 application. The wording “linkage disequilibrium” as used herein indicates the non-random association of alleles at two or more loci, not necessarily on the same chromosome, and relates to a situation in which some combinations of alleles or

genetic markers occur more or less frequently in a population than would be expected from a random formation of haplotypes from alleles based on their frequencies. Non-random associations between polymorphisms at different loci are measured by the degree of linkage disequilibrium (LD). Genetic variations in linkage disequilibrium indicated in the present disclosure have degree of linkage disequilibrium r^2 ranging from 0.9-1 and can be identified by a skilled person using GenBank sources upon reading of the present disclosure.

In some embodiments, the effects of genetic variations on an individual's response to rostavuroxin are considered in methods to perform or evaluate a rostavuroxin therapy herein described. The terms "therapy", "therapeutic" therapeutically" and related as used herein indicate an item of or relating to the treatment or prevention of a condition in an individual, and in particular when referred to rostavuroxin, indicate an item of or relating to the treatment or prevention of a condition associated to any biological activity associated to rostavuroxin in the individual.

The term "condition" as used herein indicates as usually the physical status of the body of an individual (as a whole or of one or more of its parts) that does not conform to a physical status of the individual (as a whole or of one or more of its parts) that is associated with a state of complete physical, mental and possibly social well-being. Conditions herein described include but are not limited disorders and diseases wherein the term "disorder" indicates a condition of the living individual that is associated to a functional abnormality of the body or of any of its parts, and the term "disease" indicates a condition of the living individual that

impairs normal functioning of the body or of any of its parts and is typically manifested by distinguishing signs and symptoms. Exemplary conditions include but are not limited to injuries, disabilities, disorders (including mental and physical disorders), syndromes, infections, deviant behaviors of the individual and atypical variations of structure and functions of the body of an individual or parts thereof.

The wording "associated to" as used herein with reference to two items indicates a relation between the two items such that the occurrence of a first item is accompanied by the occurrence of the second item, which includes but is not limited to a cause-effect relation and sign/symptoms-disease relation.

Conditions associated to a biological activity which is associated to rosfuroxin in an individual include but are not limited to cardiovascular conditions (e.g. hypertension, including primary hypertension, cardiac hypertrophy, increased vascular resistances and arterial restenosis) renal failure, glomerulosclerosis, proteinuria, polycystic renal disease, retinal damage, cerebrovascular disorders, Meniere syndrome, cognitive disorders, bipolar disorders and cardiovascular complications associated to primary hypertension such as cardiac failure, stroke, ischemia, retinal damage and additional conditions identifiable by the skilled person.

The wording "primary hypertension" indicates a clinical condition affecting 25-30% of the adult population in industrialized societies and through its cardiac, cerebral and renal complications is responsible for a large proportion of health burdens and costs, and includes grade I, II, III, IV of hypertension based on the level of blood

pressure and the presence of the associated vascular, retinal complications identifiable by a skilled person.

The term “treatment” as used herein indicates any activity that is part of a medical care for, or that deals with, a condition medically or surgically. The term

5 “prevention” as used herein indicates any activity, which reduces the burden of mortality or morbidity from a condition in an individual. This takes place at primary, secondary and tertiary prevention levels, wherein: a) primary prevention avoids the development of a disease; b) secondary prevention activities are aimed at early disease treatment, thereby increasing opportunities for interventions to prevent
10 progression of the disease and emergence of symptoms; and c) tertiary prevention reduces the negative impact of an already established disease by restoring function and reducing disease-related complications.

In particular, in some embodiments, information concerning SNPs in an individual’s genotype is used as a method for treating or preventing a cardiovascular condition
15 in the individual. In those embodiments rosfuroxin is administered or prescribed to the individual who has been determined to be a carrier of at least one polymorphism selected from the group consisting of the core SNPs rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375 or of a genetic variation in linkage disequilibrium therewith.

20 In particular, in several embodiments, individuals carrying one or more of the core SNPs exhibit an improved response to rosfuroxin in the individual that can be calculated on the basis to the quantitative phenotype formed by the average

decrease in blood pressure in an individual measured following therapy with respect to treatment with placebo (DSBP5_0) of at least 15 mmHg as illustrated extensively in the Examples section.

Based on a quantitative phenotype DSBP5_0 in several embodiments, individuals
5 carrying one or more of the core SNPs exhibit an improved response defined by a magnitude of the average blood pressure drop (significantly compared to values before treatment) obtained with rosfuroxin that is about 40% or more and in particular about 40% to 50% or more, than the average blood pressure drop obtained with other antihypertensive agents such as HCTZ or Losartan in never
10 treated patients.

In several embodiments, individuals carrying one or more of the core SNPs exhibit an improved response to rosfuroxin in the individual that can be calculated on the basis to the quantitative phenotype formed by the average decrease in nightly blood pressure in an individual measured following therapy with respect to
15 treatment with placebo (DSBP5_0) of at least 9 mmHg as illustrated extensively in the Examples section.

Additionally, since the DSBP5_0 is the quantitative phenotype of the statistical and experimental analysis reported in the Examples section, the improved response to rosfuroxin defined by average drop in blood pressure is considered
20 representative of any improved response defined by any biological activities associated to rosfuroxin that are detectable using biomarkers or clinical information other than blood pressure measurement. Therefore improved

responses defined by biological activities of rostaduroxin detectable using biomarkers or clinical information other than blood pressure measurement are comprised within the scope of the present disclosure and identifiable by a skilled person.

- 5 In some embodiments of the methods and systems herein described an improved response to rostaduroxin is achieved by administering or prescribing rostaduroxin to an individual carrying one or more of the following core SNPs: nucleotide C or T in position 18079898 of chromosome 6 (rs2345088), nucleotide C or T in position 11753617 of chromosome 7 (rs16877182), nucleotide G or A in position 82560511
10 of chromosome 6 (rs16893522), nucleotide G or A in position 57078480 of chromosome 10 (rs2461911), nucleotide C or T in position 29928565 in chromosome 6 (rs5013093), and nucleotide T or G in position 148244380 of chromosome 4 (rs12513375).

- In some embodiments of the methods and systems herein described rostaduroxin is
15 administered or prescribed to an individual who is a carrier of at least one of the following genotypes alone or in combination with each other: genotype TT or genotype 1 for rs2345088, genotype C/T or genotype 2 for rs16877182, genotype AA or genotype 1 for rs16893522, genotype AA or genotype 1 for rs2461911, genotype TT or genotype 1 for rs5013093, and genotype TT or genotype 1 for
20 rs12513375.

In particular, the presence of at least one relevant genotype for any of the above listed SNPs, alone or in combination one with the other is associated to a

DSBNP5_0 average systolic blood pressure decrease in the individuals ranging from 23 to 12 mmHg according to the doses or the combination of genotypes (profiles see Examples section).

In several embodiments, one or more of the core SNPs and/or genetic variations in linkage disequilibrium therewith can be associated with one or more additional genetic variations also affecting the response to rostavuroxin in an individual genetic variations also affecting the response to rostavuroxin in an individual and that are exemplified by the SNPs identified as CAND 1, CAND 2 and GWS described in details in the Examples section. In particular the additional genetic variations affecting the response to rostavuroxin in the individuals comprise groups of genes directly or indirectly involved in Adducin expression and Endogenous Ouabain (EO) synthesis and transport Those genes include but are not limited to CAND 1 genes such as ADD1, ADD2, ADD3, LSS, CYP11A1, HSD3B1-2 SLCO4C1, MDR1 and related polymorphisms.

In several embodiments of the methods and systems herein described an improved response to rostavuroxin is detected in connection with administering or prescribing rostavuroxin to an individual carrying at least one of the following additional relevant CAND 1 SNPs alone or in combination with the core SNPs: rs4961, rs4984, rs3731566, rs914247, and rs1045642 and/or of a genetic variation in linkage disequilibrium therewith.

In particular, in some embodiments of the methods and systems herein described an improved response to rostavuroxin is detected in connection with administering

or prescribing rosetafuroxin to an individual who is a carrier of at least one of the following CAND 1 genotypes alone or in combination with a genotype for core SNPs: GT for rs4961, CT for rs4984, AG for rs3731566, GA for rs914247, and TC for rs1045642. In particular, an improved response to rosetafuroxin is detected in connection with administering or prescribing rosetafuroxin to an individual who is a carrier of CAND 1 genotype AA for rs914247.

In several embodiments of the methods and systems herein described an improved response to rosetafuroxin is detected in connection with administering or prescribing rosetafuroxin to an individual carrying at least one of the following additional relevant CAND 2 SNPs alone or in combination with the core SNPs: rs242093, rs1996396, rs10503806, rs13251780, rs17430706, rs10102024, rs526302, rs544104, rs3102087, rs5183, rs3772627, rs2276736, rs2131127, rs3741559, rs2217342, rs10927888, rs6604909, rs945403, rs7117314, rs10790212, rs11216598, rs910682, rs13218316, rs4309483, rs13280307, rs4739037, rs17596774, rs2728108, rs17786456, rs7696304, rs2725222, rs17199565, rs2758152, rs1057293, rs16960712, rs759359, rs404214, rs1005213, rs17025453, rs2110923, rs1428571, rs435404, rs12908787, rs11647727, rs880054, and rs11064584 and/or of a genetic variation in linkage disequilibrium therewith.

In several embodiments of the methods and systems herein described an improved response to rosetafuroxin is detected in connection with administering or

prescribing rostafuroxin to an individual carrying at least one of the following additional relevant GWS SNPs alone or in combination with the core SNPs:

rs12996186, rs9893372, rs7216331, rs7521668, rs188334, rs4998662,
rs16893522, rs6457110, rs3893464, rs2517718, rs1362126, rs5013093,
5 rs2345088, rs6718282, rs721207, rs2555500, rs2461911, rs8179654, rs1901139,
rs2427832, rs9361863, rs1998394, ga001619, rs2275531, rs748140, rs4710592,
rs2743951, rs10159569, rs3087816, rs10493940, rs16877182, rs2326912,
rs1110446, rs12513375, rs17414954 or of a genetic variation in linkage
disequilibrium therewith.

- 10 In some embodiments of the methods and systems herein described an improved response to rostafuroxin is detected in connection with administering or prescribing rostafuroxin to an individual carrying at least one of the following additional relevant SNPs alone or in combination with the core SNPs: Rs4961, Rs4984, Rs10923835, Rs947130, Rs914247, Rs1045642, Rs880054, Rs10502933, Rs2131127,
15 Rs4309483, and Rs4739037 or of a genetic variation in linkage disequilibrium therewith.

- More particularly, in some embodiments of the methods and systems herein described an improved response to rostafuroxin is achieved by administering or prescribing rostafuroxin to an individual carrying at least one of the following
20 additional relevant SNPs alone or in combination with the core SNPs: nucleotide G or T for Rs4961, nucleotide G or A for Rs4984, nucleotide A or T for Rs10923835, nucleotide C or T for Rs947130, nucleotide A or G for Rs914247, nucleotide C or T

for Rs1045642, nucleotide C or T for Rs880054, nucleotide C or T for Rs10502933, nucleotide C or T for Rs2131127, nucleotide C or A for Rs4309483, and nucleotide G or A for Rs4739037.

More particularly, in some embodiments of the methods and systems herein
5 described rostaduroxin is administered or prescribed to an individual who is a carrier of at least one of the following genotypes alone or in combination with a genotype for core SNPs: genotype GT or genotype TT for Rs4961, genotype CC for Rs4984, genotype AT or genotype TT for Rs10923835, genotype GG for Rs947130, genotype AA for Rs914247, genotype TT for Rs1045642, genotype AG
10 or genotype GG for Rs880054, genotype CT for Rs10502933, genotype CC for Rs2131127, genotype AA for Rs4309483, and genotype GA for Rs4739037.

In particular, in several embodiments of the method for treating an individual with rostaduroxin is described. The method comprises: administering or prescribing rostaduroxin to the individual in a dosage of from 0.005 mg/day to 5 mg/day,
15 preferably 0.01 mg/day to 1.5 mg/day, most preferably 0.05 mg/day to 0.5 mg/day. Dosage treatment can be performed on a single dose schedule or a multiple dose schedule, according to the physician judgment.

In particular, in several embodiments lower doses (such as 0.05 mg/day; 0.15 mg/day; 0.5 mg/day) can be more efficient in reducing systolic blood pressure than
20 the high doses (1.5 mg/day; 5.0 mg/day) in the subset of individuals carrying the genetic variations herein described, with an average decrease in systolic blood

pressure of approximately 18 mmHg as compared with -12 mmHg induced by high doses.

In particular, in several embodiments hypertensive individuals carrying previously identified genotypes comprising at least one polymorphism selected from the core
5 SNPs dosage of rostaduroxin comprised from 0.05 to 0.5 mg/day produces a blood pressure drop ranging from -12 to -34 mmHg and dosages comprised from 1.5 mg/day to 5 mg/day produces a blood pressure drop ranging from -0.6 to -23 mmHg.

Accordingly, in several embodiments, individuals carrying all core SNPs low
10 dosages provide a greater response (-23 mmHg average) with respect to high dosages (-15 mmHg average).

In several embodiments, following treatment with rostaduroxin individuals carrying genetic variations herein described exhibit a decrease in blood pressure of at least 10% compared to the detected blood pressure before rostaduroxin treatment.

15 In several embodiments, following treatment with rostaduroxin individuals carrying genetic variations herein described exhibit an average decrease in the office blood pressure and/or nightly blood pressure of the individual of at least about 15 and about 9 mmHg, respectively.

In several embodiments, individuals carrying genetic variations herein described
20 exhibit a normalization of the blood pressure below 140 mmHg for the systolic blood pressure and below 90 mmHg for the diastolic blood pressure.

In several embodiments, following treatment with rostafuroxin individuals carrying genetic variations herein described exhibit an average blood pressure decrease that is about 40% higher than an average blood pressure decrease obtained with HCTZ or Losartan (see Example 2).

5 In methods and systems herein described rostafuroxin can be comprised compositions to be administered individually to a patient and/or that can be administered in combination with other agents, drugs or hormones. In particular, in some embodiments the medicament can also contain a pharmaceutically acceptable carrier, selected from the carriers suitable for administration of a
10 therapeutic agent. A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N. J.1991) herein incorporated by reference in its entirety.

Pharmaceutically acceptable carriers in therapeutic compositions can additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary
15 substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the individual.

20 The medicament comprising rostafuroxin can be administered in methods herein described by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular,

transdermal or transcutaneous applications, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, rectal means or locally on the diseased tissue after surgical operation. The compound of the invention may also be applied (coated) on the stent even incorporated into a controlled-release matrix.

5 In several embodiments, the expected therapeutic effects in term of treatment and prevention that follows administration of rosfuroxin in individuals carrying at least one of the core SNPs and/or genetic variation in linkage disequilibrium therewith can include but are not limited to: prevention or reduction of cardiac hypertrophy and insufficiency, cardiac ischemia, increased vascular reactivity, vascular
10 stiffness, increased vascular thickness, renal hypertrophy, renal failure, glomerulosclerosis, proteinuria, cerebrovascular damage, stroke, cognitive disorders, retinal damage. Such effects are expected since all the above mentioned disorders are directly or indirectly consequent to the pathological increase of blood pressure (grade III and IV of hypertension) which is normalized
15 by rosfuroxin in individuals carrying the core SNPs alone or in combination with each others, with CAND1 SNPs, CAND2 SNPs, selected GWS SNPs and/or genetic variations in linkage disequilibrium therewith. In addition, due to the ability of rosfuroxin to antagonize some mechanisms of hypertension such as increased renal sodium reabsorption and activation of the Src signal transduction pathway,
20 organ damages other than those directly caused by high blood pressure can be prevented by the treatment. For instance, individuals carrying the ADD1 Trp460 genetic variant, for the same level of blood pressure, display a higher incidence of

cardiovascular complications than carrier of the Gly460 ADD1 variant. Also hypertensive individuals with high levels of plasma ouabain display higher rate of cardiovascular complications than individuals with low ouabain plasma level but similar blood pressure levels. Even though the precise mechanisms of the increased blood pressure drop after rostafuroxin in individuals carrying at least one of the selected core SNPs are not known, they must be related to the mechanisms triggered by the molecular targets hit by rostafuroxin. As consequence, benefits beyond those related to the blood pressure drop induced by rostafuroxin are expected in individuals carrying at least one of the core SNPs genotypes.

10 In some embodiments, in the individuals carrying at least one of the core SNPs, dosages of rostafuroxin ranging from 0.05 to 0.15 mg/day (low doses) are expected to induce a greater blood pressure drop than higher doses such as those ranging from 1.5 to 5 mg/day (high doses). In particular, the low doses are expected to produce an average blood pressure drop of about 23 mmHg while the

15 high doses are expected to produce an average blood pressure drop of about 15 mmHg. In addition, In the individuals carrying at least one of the core SNPs these dosages of rostafuroxin are expected to prevent the development of cardiovascular complications associated but not only to hypertension such as cardiac hypertrophy, cardiac failure, increased vascular resistances, renal failure,

20 glomerulosclerosis, proteinuria, polycystic renal disease, retinal damage, cerebrovascular disorders, Meniere syndrome, cognitive disorders, bipolar disorders.

In some embodiments, rostafuroxin treatment to an individual carrying at least one of the core SNPs can be performed in a dosage of μg per day ranging from 5 μg to 50000 μg , preferably 10 μg to 15000 μg , most preferably 50 μg to 500 μg .

According to the dosages, low doses ranging from 0.05 to 0.50 mg/day (low doses) result in a higher (+50%) response in term of blood pressure drop as compared to high doses ranging from 1.5 to 5 mg/day (high doses). In addition, low doses produce a relevantly higher drop of night blood pressure as compared to high doses.

In some embodiments, administration of rostafuroxin to an individual carrying at least one of the core SNPs in combination with each other and/or with other relevant SNPs such as those included in the CAND1, 2 and GWSA SNPs (see profile 8 and 9, example 2), rostafuroxin is expected to induce an average blood pressure decrease ranging from about 8 to about 22.5 mmHg.

In some embodiments, administration of rostafuroxin to an individual carrying at least one of the core SNPs in combination with each other and in association with other relevant SNPs such as those included in the CAND1, CAND 2 and GWS SNPs (see profiles 8 and 9, Example 2), rostafuroxin is expected to induce a average blood pressure drop of the office (systolic, daily) blood pressure 23 mmHg and of the nightly blood pressure of about 9 mmHg.

In some embodiments, administration of rostafuroxin to an individual carrying at least one of the core SNPs alone or in combination with each other or additional relevant SNPs, results in an improved response to rostafuroxin if compared with

the response of the individual to other hypertensive drugs such as Losartan or Hydrochlorothiazide. In particular, administration of rostaduroxin to individuals carrying at least one of the core SNPs alone or in combination with each other (or additional relevant SNPs) is expected to produce a blood pressure drop at least 5 40% higher than those produced by Losartan or HCTZ, respectively (see Example 2) in never treated patients.

In some embodiments a method for evaluating therapy herein described comprises obtaining sequence information regarding at least one polymorphism .selected from the group consisting of the core SNPs: rs16877182, rs5013093, rs2461911, 10 rs12513375, rs16893522, rs2345088, wherein the information is predictive of rostaduroxin efficacy in the individual.

In some embodiments, sequence information can be obtained also for additional relevant genetic variations affecting the response to rostaduroxin such as SNPs of CAND1 genes, CAND2 genes and/or GWS genes, which include but are not 15 limited to rs4961 (ADD1) , rs4984 (ADD2) , rs3731566 (ADD3) , rs914247 (LSS2), rs1045642 (MDR2) , rs10502933, rs2131127, rs4309483, rs4739037 and additional SNPs. Identifiable by a skilled person upon reading of the present disclosure (additional SNPs from profiles 8-9: rs10923835 (HSD18), rs947130 (HSD19), rs880054 (WNK1).

20 In some embodiments, sequence information comprise at least one of the sequences SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID NO: 11 and an improved response to rostaduroxin can be

predicted with corresponding detected sequence information such as SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12 respectively.

More particularly, in embodiments where sequence information comprise at least one of the sequences SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID NO: 11 and an improved response to rostaturoxin can be predicted with corresponding detected allelic sequence information comprising SEQ ID NOs: 13 and 14 for SEQ ID NO: 1, SEQ ID NOs: 15 and 16 for SEQ ID NO: 3, SEQ ID NOs: 17 and 18 for SEQ ID NO: 5, SEQ ID NOs: 19 and 20 for SEQ ID NO: 7, SEQ ID NOs: 21 and 22 for SEQ ID NO: 9, and SEQ ID NOs: 23 and 24 for SEQ ID NO: 11.

In several embodiments, the method comprises obtaining sequence information for at least one polymorphism selected from the group consisting of rs4961, rs4984, rs10923835, rs947130, rs914247, rs1045642, rs880054, rs10502933, rs2131127, rs4309483, and rs4739037. In particular, in several embodiments, additional relevant sequence information further comprise SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43 and SEQ ID NO: 45, and an improved response to rostaturoxin can be predicted with corresponding detected sequence information such as SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46, respectively.

More particularly, in embodiments where sequence information comprise at least one of the sequences SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43 and SEQ ID NO: 45, an improved response to rostafuroxin
5 can be predicted with corresponding detected allelic sequence information comprising SEQ ID NOs: 47 and 48 for SEQ ID NO: 25, SEQ ID NOs: 49 and 50 for SEQ ID NO: 27, SEQ ID NOs: 51 and 52 for SEQ ID NO: 29, SEQ ID NOs: 53 and 54 for SEQ ID NO: 31, SEQ ID NOs: 55 and 56 for SEQ ID NO: 33, SEQ ID NOs: 57 and 58 for SEQ ID NO: 35, SEQ ID NOs: 59 and 60 for SEQ ID NO: 37,
10 SEQ ID NOs: 61 and 62 for SEQ ID NO: 39, SEQ ID NOs: 63 and 64 for SEQ ID NO: 41, SEQ ID NOs: 65 and 66 for SEQ ID NO: 43, and SEQ ID NOs: 67 and 68 for SEQ ID NO: 45.

In particular, sequence information can be obtained using genotype analysis: GenChip from ILLUMINA or additional methods and systems identifiable by a
15 skilled person. In some embodiments, the method for evaluating rostafuroxin therapy herein disclosed can be performed by a system that comprises probes for the core SNPs sequence information or a portion thereof such as the primers from SEQ ID NO: 35 to SEQ ID NO: 58 listed in Example 8 below.

In some embodiments, the method to evaluate treatment with rostafuroxin
20 comprises the selection of the hypertensive patients who should be either men or women, with age of at least 18 years, of various ethnicity including Caucasian but also African, Asian or Afro-American, preferentially with, but not limited to, grade I

or II of primary hypertension, untreated or on treatment with only one drug or one combination tablet containing no more than two antihypertensive agents, without severe or malignant hypertension or secondary hypertension (which includes a history of renal arterial disease), without associated conditions and no more than
5 two additional cardiovascular risk factors, without surgery or diseases of the gastrointestinal system which might influence the absorption or hepatic clearance of rostaduroxin, not on treatment with any other investigational drug from at least 6 months before rostaduroxin administration. Patients can be treated according to the 2003 guidelines of the European Society of Hypertension and the European
10 Society of Cardiology [Ref. 7].

Blood pressure can be monitored under ambulatory conditions according to the recommendations of the European Society of Hypertension for conventional and ambulatory blood-pressure measurement [Ref.8]. Measurement of blood pressure can be performed by employing oscillometric recorders or any other validated
15 ambulatory recorder or sphygmomanometer. Blood pressure should be monitored at the arm after the patient has rested for at least 5 min in the sitting position. Genotype of the patients can be measured on a blood sample taken at the brachial vein. The DNA will be extracted from the blood according to standard procedure [Ref.9] or with the use of custom kit (for example Promega genomic DNA
20 purification Cat A2360 or Qiagen PAXgene Blood DNA Kit), stored and genotyped for the SNP of interest using a selected nuclease detection assay (e.g. ABI assay

on demand for allelic discrimination). In some embodiments sequence information can be derived using methods identifiable by a skilled person.

Individuals carrying at least one of the core SNPs, and in particular the selected genotype herein described, alone or in association with each other, and/or
5 additional relevant SNPs belonging to CAND 1, CAND2 and GWS SNPs, and in particular the selected genotype herein described, and/or having related sequence information are treated with rostavuroxin by administering the substance in a defined pharmaceutical composition, once a day, by oral route, in a dosage ranging from 0.05 to 5 mg/day, preferably in the morning between 7.00 and 9.00
10 a.m.. The treatment can last from at least 5 weeks to the entire patient's life.

In some embodiments, the effects of genetic variations on rostavuroxin activity form the basis for a method for predicting a response to rostavuroxin in an individual. The method comprises: detecting a genotype in the individual for an intergenic or intragenic region of a gene selected from the group consisting of KCNS3,
15 THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and comparing the detected genotype with previously identified genotypes associated with a known response to rostavuroxin, the previously identified genotypes comprising at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375.

20 The term "detect" or "detection" and "detectable" as used herein indicates the determination of the existence, presence or fact of a compound, a sequence or genotype, in a limited portion of space, including but not limited to a tissue sample,

a reaction mixture, a molecular complex and a substrate. A detection is “quantitative” when it refers, relates to, or involves the measurement of quantity or amount of the compound (also referred as quantitation), which includes but is not limited to any analysis designed to determine the amounts or proportions of the compound. A detection is “qualitative” when it refers, relates to, or involves identification of a quality or kind of the compound in terms of relative abundance to another target or signal, which is not quantified.

Detecting a genotype can be performed according to several techniques identifiable by a skilled person. In general the methods for single SNP analysis are PCR-RFLP analysis, DNA sequencing, Taqman assay, kinetic PCR. One of this method, the Taqman Assay (assay on demand and custom MGB probe and primer design from ABI) was used in the present report to genotype CAND1 SNPs (Example 3) and ADD1, ADD2, HSD18, HSD19, LSS2, MDR2, WNK genes (Example 4).

The assay for multiple SNP analysis utilizes several commercial platform and available or custom Gene-Chip with variable number of genes (hundreds to millions) for each chip. In the present disclosure the HumanHap 1M Duo chip genotyping Beads Chip and the Illumina Infinium II Technology was used to genotype the SNPs in Example 4 (rs10502933, rs2131127, rs4309483, rs4739037) and Examples 5 and 6.

In the method, if the genotype detected in the individual is the same genotype associated with the rostaduroxin response, the response of the individual to

rostafuroxin predicted to be the known response. The term “response” as used herein, with reference to rostafuroxin, indicates any fact any action or change of condition in the individual that are associated to the administration of rostafuroxin to the individual. Exemplary response to rostafuroxin in an individual comprises

5 blood pressure drop clinically relevant. In particular, a blood pressure drop significantly higher than that caused by placebo and specifically at least equal to 10% of the blood pressure value before treatment or able to bring the blood pressure values equal or lower than 140 mmHg for systolic or 90 mmHg for diastolic blood pressure. In some embodiments, the method can further comprise

10 detecting, e.g. in the isolated DNA of the individual a genotype in the individual for an intergenic or intragenic region of a gene selected from the group consisting of ADD1, ADD2, ADD3, CYP11A1, HSD3B1, LSS, ABCB1/MDR1, SLCO4C; and comparing the detected genotype with previously identified genotypes associated with a known Rostafuroxin response, the previously identified genotypes

15 comprising at least one polymorphism selected from the group consisting of rs4961, rs4984, rs3731566, rs914247, rs1045642 and/or of a genetic variation in linkage disequilibrium therewith. In some embodiments, the method can further comprise detecting a genotype in the individual for an intergenic or intragenic region of a gene selected from the group consisting of ACTN1, ADRA1A, AGTR1,

20 AQP2, ATP1A3, CLCNKA, CLCNKB, FXYD2, FXYD6, FYN, NEDD4L, NKAIN3, PKD1, PKD2, SCNN1B, SGK1, SLC12A1, SLC8A1, TJP1, UMOD, and WNK1; and comparing the detected genotype with previously identified genotypes

associated with a known Rostafuroxin response, the previously identified genotypes comprising at least one polymorphism selected from the group consisting of rs242093, rs1996396, rs10503806, rs13251780, rs17430706, rs10102024, rs526302, rs544104, rs3102087, rs5183, rs3772627, rs2276736, 5 rs2131127, rs3741559, rs2217342, rs10927888, rs6604909, rs945403, rs7117314, rs10790212, rs11216598, rs910682, rs13218316, rs4309483, rs13280307, rs4739037, rs17596774, rs2728108, rs17786456, rs7696304, rs2725222, rs17199565, rs2758152, rs1057293, rs16960712, rs759359, rs404214, rs1005213, rs17025453, rs2110923, rs1428571, rs435404, rs12908787, rs11647727, 10 rs880054, and rs11064584 and/or of a genetic variation in linkage disequilibrium therewith. In some embodiments, the method can further comprise detecting a genotype in the individual for an intergenic or intragenic region of a gene selected from the group consisting of ARL5A, ATP2A3, COX10, DPH5, FAIM3, FAM46A, HCG9, HLA-A, HLA-F, HLA-G, KCNS3, LOC131691, LOC389174, LOC389970, 15 LOC642727, LOC644192, LOC649458, LOC728360, LOC728316, PIGR, RCADH5, RP3-377H14.5, SH3PXD2A, SLC30A7, THSD7A, TMEM200A, TRIM31, TTC29, and VCAM1; and comparing the detected genotype with previously identified genotypes associated with a known Rostafuroxin response, the previously identified genotypes comprising at least one polymorphism selected 20 from the group consisting of rs12996186, rs9893372, rs7216331, rs7521668, rs188334, rs4998662, rs16893522, rs6457110, rs3893464, rs2517718, rs1362126, rs5013093, rs2345088, rs6718282, rs721207, rs2555500, rs2461911, rs8179654,

rs1901139, rs2427832, rs9361863, rs1998394, ga001619, rs2275531, rs748140, rs4710592, rs2743951, rs10159569, rs3087816, rs10493940, rs16877182, rs2326912, rs1110446, rs12513375, and rs17414954 and/or of a genetic variation in linkage disequilibrium therewith.

- 5 In some embodiments, the method for predicting a response to rostaduroxin herein disclosed can be performed by a system that comprises a first component for genotyping that is applied only once for the classification of patients in responders and not responders, and a composition comprising rostaduroxin and a pharmaceutical acceptable carrier at the doses ranging from 50-500 γ daily.
- 10 In some embodiments, a system for predicting a response of an individual to rostaduroxin can comprise a probe for at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375 and a look-up table associating results of probes hybridization and previously identified genotypes.
- 15 In some of those embodiments, the probe comprises at least one isolated polynucleotide selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12 or a fragment thereof, the fragment capable of specifically hybridizing a sequence complementary to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8,
20 SEQ ID NO: 10 or SEQ ID NO: 12.

In of those embodiments, the system can further comprise a probe for at least one polymorphism selected from the group consisting of rs4961, rs4984, rs10923835,

rs947130, rs914247, rs1045642, rs880054, rs10502933, rs2131127, rs4309483, and rs4739037.

In particular, the probe can comprise at least one isolated polynucleotide selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, 5 SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46 or a fragment thereof, the fragment capable of specifically hybridizing a sequence complementary to SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44 or SEQ 10 ID NO: 46. In some embodiments, the probes can have a sequence selected from the group consisting of SEQ ID NO: 35 to SEQ ID NO: 58.

In several embodiments the system can comprise tubes for blood samples collection, buffers for genomic DNA extraction, DNA amplification (e.g. primers, buffer, and/or dNTP enzymes) and additional components identifiable by a skilled 15 person.

In several embodiments, several procedures can be used for single SNP analysis comprising: a) Real-time PCR SNP genotyping with allele specific MGB probes using Pre-Designed SNP assay or custom SNP Genotyping Assay from ABI and a real-time PCR system for data analysis; b) Allele specific PCR SNP with universal 20 energy transfer primers (Amplifluor technology) and real time PCR system for data analysis; c) PCR-RFLP analysis and agarose-gel detection; d) kinetic PCR; and e) direct sequencing. Additional procedures that are suitable to perform single SNP

analysis are identifiable by a skilled person and will not be discussed in further details.

In several embodiments the systems can comprise custom services of gene-chip (micro-array) from ILLUMINA, AFFIMETRIX or ABI or other specialized companies, 5 can be used. For our purpose the number of SNPs to include in a single gene-chip could be relative low (20-30). The main components to assemble a specific gene-chip are based on five major processes: DNA purification, PCR amplification of purified DNA with specific primer mix; fragmentation and labeling of the amplified products; hybridization of the amplified products to the microarray and staining of 10 the bound products, scanning and analysis of the microarray.

In some embodiments, the effects of genetic variations on rostafuroxin activity form the basis for a method for identifying an individual with improved response to rostafuroxin. The method comprises detecting a single nucleotide polymorphism (SNP) in any one of the nucleotide sequences of SEQ ID NO 1, SEQ ID NO 3, 15 SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 9, and SEQ ID NO 11 in intergenic or intragenic regions of the individuals, wherein the presence of the core SNPs is correlated with an improved response to rostafuroxin in said individual. In several embodiments additional relevant SNPs herein described can also be detected in the method for identifying an individual with improved response to rostafuroxin.

20 In some embodiments, the effects of genetic variations on rostafuroxin activity form the basis for a method for improving a therapeutic response to rostafuroxin in an individual with a cardiovascular condition. The method comprises administering

rostafuroxin to said individual, wherein said individual has been determined to be a carrier of at least one of the core SNPs and/or of a genetic variation in linkage disequilibrium therewith.

In some embodiments, the effects of genetic variations on rostafuroxin activity form the basis for a method for treating an individual with rostafuroxin. The method comprises: obtaining information indicating the presence of the core SNPs and optionally on the additional SNPs affecting rostafuroxin response in an individual and administering rostafuroxin for the individual having a genotype associated with the improved response in a dosage ranging from 0.005 mg to 50 mg, preferably 0.01 mg to 15 mg, most preferably 0.05 mg to 5 mg.

In some embodiments, the effects of genetic variations on rostafuroxin activity form the basis for a method for treating an individual with a cardiovascular condition. The method comprises: administering or prescribing to the patient an effective amount of rostafuroxin, wherein the patient is a carrier of at least one core SNPs and/or of a genetic variation in linkage disequilibrium therewith.

In some embodiments, the cardiovascular condition is hypertension and the method for treating an individual can be performed by

- a) obtaining a nucleic acid sample from an individual suffering from hypertension;
- b) determining the presence in said nucleic acid sample of one or more of the polymorphisms selected from the groups consisting of: the core SNPs herein described;

c) administering a pharmaceutically active amount of rostavuroxin to the patients that have shown to possess at least one polymorphism selected from the groups consisting of the core SNPs herein described.

In methods for treating individuals herein disclosed, rostavuroxin is typically administered in the form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound and a vehicle. The term "vehicle" as used herein indicates any of various media acting usually as solvents, carriers, binders, diluents or excipients for a rostavuroxin compound comprised in the composition as an active ingredient. A person skilled in the art is aware of a whole variety of such solvents carrier, diluent or excipient compounds suitable to formulate a pharmaceutical composition.

rostavuroxin together with a conventionally employed adjuvant, carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous use). Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the

active ingredient commensurate with the intended daily dosage range to be employed.

In some embodiments rostavuroxin is administered in a "pharmaceutically effective amount". The amount of the compound actually administered will typically be
5 determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, drug combination, the age, body weight, and response of the individual patient, the severity of the patient's symptoms, and the like. Generally, an effective dose is from 0.005 mg to 50 mg, preferably 0.01 mg to 15 mg, most preferably 0.05 mg to 5 mg as single
10 administration per day.

Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones. The effective dosages of the composition to be administered to a patient range from 0.05 mg to 5 mg/day.

Depending on the intended route of delivery, rostavuroxin is preferably formulated
15 as parenteral, topical or oral compositions, more preferably as oral formulation. The compositions for oral administration may take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human
20 subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include refilled,

pre-measured ampoules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the compound of the invention is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.

Dosage treatment may be a single dose schedule or a multiple dose schedule.

Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like.

Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, acacia, gum tragacanth, gelatine or polyvinyl-pyrrolidone; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or potato or corn starch; a lubricant such as magnesium stearate, talc, polyethylene glycol or silica; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as pepper-mint, methyl salicylate, or orange flavoring. The tablets may be coated according to methods well known from people skilled in the art of pharmaceutical practice.

Parenteral compositions are typically based upon injectable sterile saline or phosphate- buffered saline or other injectable carriers known in the art. As mentioned above, the compounds of formula I in such compositions are typically a

minor component, frequently ranging between 0.05 to 10% by weight with the remainder being the injectable carrier and the like.

Rostafuroxin can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can also be found in the incorporated materials in Remington's Pharmaceutical Sciences.

The above-described components for orally administered or parenteral compositions are merely representative. Further materials as well as processing techniques and the like are set out in Part 5 of Remington's Pharmaceutical Sciences, 20th Edition, 2000, Marck Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference in its entirety.

In some embodiments, an isolated nucleic acid molecule comprising at least 100 contiguous nucleotides, is disclosed wherein one of the nucleotides is a single nucleotide polymorphism (SNP) selected in any one of the nucleotide sequences SEQ ID NO 1, SEQ ID NO 3, SEQ ID NO5, SEQ ID NO7, SEQ ID NO9 and SEQ ID NO 11, or a complement thereof.

In some embodiments, the effects of genetic variations on rostafuroxin activity form the basis for a method for identifying an agent useful in therapeutically or prophylactically treating a cardiovascular condition is disclosed.

The method comprises providing a candidate agent; administering the candidate agent to an individual carrying at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093,

rs12513375 or a polymorphism in linkage disequilibrium therewith and detecting the individual response to said candidate agent.

In several embodiments, the candidate agent is administered to an individual carrying also one or more of the CAND 1, CAND2 and GWS SNPs herein
5 indicated.

In several embodiments, the method can be performed by selecting hypertensive patients and performing measurements and detection according to procedures used to evaluate treatment with rostaduroxin in individuals. In some of those
10 embodiments, evaluating rostaduroxin treatment in an individual can be performed by obtaining sequence information regarding at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375 wherein the information is predictive of rostaduroxin efficacy in the individual.

In some of those embodiments, the sequence information comprises at least one
15 of the sequences SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID NO: 11, and an improved response to rostaduroxin can be predicted with at least one corresponding detected sequence information selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12.

20 In some of those embodiments, an improved response to rostaduroxin can be predicted with at least one corresponding detected allelic sequence information selected from the group consisting of SEQ ID NOs: 13 and 14 for SEQ ID NO: 1,

SEQ ID NOs: 15 and 16 for SEQ ID NO: 3, SEQ ID NOs: 17 and 18 for SEQ ID NO: 5, SEQ ID NOs: 19 and 20 for SEQ ID NO: 7, SEQ ID NOs: 21 and 22 for SEQ ID NO: 9, and SEQ ID NOs: 23 and 24 for SEQ ID NO: 11.

In some of those embodiments, the evaluating method can further comprise
5 obtaining sequence information for at least one polymorphism selected from the group consisting of rs4961, rs4984, rs10923835, rs947130, rs914247, rs1045642, rs880054, rs10502933, rs2131127, rs4309483, and rs4739037. In particular, the sequence information can comprise at least one of the sequences SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35,
10 SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43 and SEQ ID NO: 45. For those sequence information an improved response to Rostafuroxin can be predicted with at least one corresponding detected sequence information selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40,
15 SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46.

In some of those embodiments an improved response to Rostafuroxin can be predicted with at least one corresponding detected allelic sequence information selected from the group consisting of SEQ ID NOs: 47 and 48 for SEQ ID NO: 25, SEQ ID NOs: 49 and 50 for SEQ ID NO: 27, SEQ ID NOs: 51 and 52 for SEQ ID
20 NO: 29, SEQ ID NOs: 53 and 54 for SEQ ID NO: 31, SEQ ID NOs: 55 and 56 for SEQ ID NO: 33, SEQ ID NOs: 57 and 58 for SEQ ID NO: 35, SEQ ID NOs: 59 and 60 for SEQ ID NO: 37, SEQ ID NOs: 61 and 62 for SEQ ID NO: 39, SEQ ID NOs:

63 and 64 for SEQ ID NO: 41, SEQ ID NOs: 65 and 66 for SEQ ID NO: 43, and SEQ ID NOs: 67 and 68 for SEQ ID NO: 45.

In some embodiments, the method for identifying an agent useful in therapeutically or prophylactically treating a cardiovascular condition herein disclosed can be performed by a system that comprises components suitable to detect and identify the relevant genetic variations as described herein.

In some embodiments, a system for detecting a single nucleotide polymorphism (SNP) in an intergenic or intragenic region a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, is disclosed. The system comprises an isolated polynucleotide which specifically hybridizes to a nucleic acid molecule containing a single nucleotide polymorphism (SNP) in any one of the nucleotide sequences SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, and at least one of a buffer for the nucleic acid molecule (such as a hybridization and/or polymerization buffer), and an enzyme to be used in combination with the nucleic acid sequence for the detection of the SNP. In particular, the enzyme can be a polymerase capable of catalyzing a polymerase chain reaction for one or more of the intergenic and/or intragenic region that are investigated.

The term hybridization as used herein indicates the process of establishing a non-covalent, sequence-specific interaction between two or more complementary strands of nucleic acids into a single hybrid, which in the case of two strands is referred to as a duplex. A specific hybridization is a hybridization resulting in a

specific sequence-sequence interaction. The wording “specific” “specifically” or “specificity” as used herein with reference to the binding of a molecule to another refers to the recognition, contact and formation of a stable complex between the molecule and the another, together with substantially less to no recognition, contact and formation of a stable complex between each of the molecule and the another with other molecules. The term “specific” as used herein with reference to a sequence of a polynucleotide refers to the unique association of the sequence with a single polynucleotide which is the complementary sequence.

The term “polymerase chain reaction” as used herein indicates any suitable technique to amplify a single or few copies of a piece of a nucleic acid across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. The method relies on thermal cycling, consisting of cycles of repeated heating and cooling of the reaction for nucleic acid melting and enzymatic replication of the nucleic acid.

In some embodiments, the system can also comprise an isolated polynucleotide that specifically hybridizes to a nucleic acid molecule containing a single nucleotide polymorphism (SNP) in any one of the nucleotide sequences SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43 and SEQ ID NO: 45.

The systems herein disclosed can be provided in the form of kits of parts. In a kit of parts, the probes, pharmaceutical compositions and other components and a substrate are comprised in the kit independently. In particular, the probes can be

included in one or more compositions, and each probe can be comprised in a composition together with a suitable vehicle carrier or auxiliary agent.

In some embodiments, buffers enzyme and suitable container can be further provided as an additional component of the kit. Additional components can include
5 labels (a molecule capable of detection, such as radioactive isotopes, fluorophores, chemiluminescent dyes, chromophores, enzymes, enzymes substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, nanoparticles, metal sols, ligands (such as biotin, avidin, streptavidin or haptens) and the like, microfluidic chip, reference standards, and additional components identifiable by a skilled person
10 upon reading of the present disclosure. In particular, the components of the kit can be provided, with suitable instructions and other necessary reagents, in order to perform the methods here disclosed. The kit will normally contain the compositions in separate containers. Instructions, for example written or audio instructions, on paper or electronic support such as tapes or CD-ROMs, for carrying out the assay,
15 will usually be included in the kit. The kit can also contain, depending on the particular method used, other packaged reagents and materials (i.e. wash buffers and the like).

Further details concerning the identification of the suitable carrier agent or auxiliary agent of the compositions, and generally manufacturing and packaging of the kit,
20 can be identified by the person skilled in the art upon reading of the present disclosure.

In the following section the present disclosure shall be illustrated by means of some examples which are not construed to be viewed as limiting the scope of the disclosure.

EXAMPLES

5 A pharmacogenomic study was performed to ascertain the effect of genetic variations on an individual response to rostavuroxin. The sample for the pharmacogenomic study consisted of 342 individuals that were genotyped with the Human1M array from Illumina using Human1M Duo CHIP genotyping Bead Chip according to procedure described in [Ref. 10, 11, 12]. Among the individuals, 169
10 were administered the placebo treatment and 173 the active drug (rostavuroxin) in the first period (5 weeks) with demographics as in [Ref 13]. In particular, patients were randomized to one of the following oral doses of rostavuroxin: 0.05, 0.15, 0.5, 1.5, or 5 mg/day for 5 weeks. Each dose had to be compared to a placebo in a crossover design. Since previous studies demonstrated that one month of washout
15 may be insufficient [Ref. 14-30] 193 patients that did not receive a previous treatment (NPT) were analyzed separately from the 149 previously treated.

For the above sample of individuals a genetic association analysis, was performed to associate the phenotype of the tested individuals with the SNPs detected in the individuals. The selected phenotype of interest was the blood pressure response.

20 The SNPs selected for detection were the 1111170 SNPs on autosomal chromosomes of the individual.

The genetic analysis was performed according to a quantitative genetic association design where the phenotype of interest is a quantitative variable (QT), and the variables (factors) affecting the distribution of the phenotype of interest are SNPs, therapy (placebo, rostaduroxin) and the SNP*therapy interaction.

5 In particular, the quantitative phenotype selected for the statistical analyses was the difference in mmHg between the office Systolic Blood Pressure (SBP) at the end of first treatment period (SBP_5) and the office Systolic Blood Pressure at baseline after one month of run-in (SBP_0) and is herein also identified as DSBP5_0. The selected QT phenotype and other factors affecting distribution of
10 the phenotype of interest were then analyzed according to the following quantitative trait interaction test

$$\text{Phenotype} = \text{SNP} + \text{therapy} + \text{SNP} * \text{therapy}$$

as illustrated in further details below.

To perform the genetic association a descriptive statistical analysis and an
15 inferential statistical analysis were carried out.

The descriptive statistical analysis was performed to first summarize and describe the main parameters of the data and perform quality controls.

Table 1 summarizes the statistical procedures, parameters and thresholds selected by Applicants in performing the analysis as well as the results obtained in
20 outcome therefrom.

Table 1: Descriptive Statistical Analysis

Procedure	Analysis/thresholds	Results
Call Rate	Number of SNPs called per sample	<u>Mean call rate</u> of 0.996651 for the 193 NPT subjects on 1M SNPs
Individual Missingness	Number of individuals with missing rate per SNP Inclusion threshold \leq 10%	<u>Individuals missing</u> : 0 of 193 individuals were removed for low genotyping (MIND>0.1)
	Number of SNPs with missing rate per individual Inclusion threshold \leq 10%	<u>Locus (SNP) missingness</u> : 6071 SNPs failed missingness test having a genotyping rate<0.9 and were not included in the analysis
Minor Allele Frequency	Lowest allele frequency at a specific locus observed in a particular population - MAF threshold of 0.05	<u>MAF</u> <0.05 for 258148 SNPs- excluded from the analysis
Hardy Weinberg equilibrium (HWE) test	HWE tested for each SNP in the whole population using the exact test, described and implemented by Wigginton et al. [Ref 31]	2510 SNPs markers failed HWE test ($p \leq 0.001$) SNPs not removed in view of sample composition (only cases) - departure from HWE could be indicative that association phenotype-SNPs is real causal.

Table 1: Descriptive Statistical Analysis

Procedure	Analysis/thresholds	Results
Stratification	Principal Component Analysis (PCA) to reduce 1M SNPs dimensions allowing clustering the individuals using top axis of variation	Mild heterogeneous clusterization of individuals distributed around zero is visible (see Figure 3)
	Genomic inflation factor, λ calculated as described in Devlin et al. [Ref 32]	Genomic inflation factor, λ reported is 1.005 indicating the absence of inflation due to the stratification, if compared with the lambda (1.757) of example of stratified population (population composed by Europeans, Africans and other or more than one racial category)

The results of the genetic descriptive analysis performed are also illustrated in **Table 2** and **Figures 1, 2 and 3** in further detail.

Table 2: Results of Descriptive Statistical Analysis

Patient Group	Basal SBP \pm SD	Mean fall in blood pressure mmHg	Std. Err.	[95% Conf. Interval]
Total (193 IDs)	150,3+/-7,5	-6.73057	.8542748	-8.415539 - 5.045601
Placebo (94 IDs)	150,0+/-7,5	-7.67766	1.174851	-10.01068 - 5.344638

Table 2: Results of Descriptive Statistical Analysis

Patient Group	Basal SBP ±SD	Mean fall in blood pressure mmHg	Std. Err.	[95% Conf. Interval]
Therapy (99 IDs)	150,6+/- 7,5	-5.831313	1.235603	-8.283328 - 3.379299

In particular, in **Table 2** the descriptive statistics of DSBP5_0 for the entire sample and for the patients treated with placebo and rosfuroxin are listed. The rather modest basal level of SBP can be explained in view of the recruitment of patients with “mild” hypertension (SBP range 140 -179 mmHg), required by the inclusion of a placebo arm. A graphic illustration of the results summarized in **Table 2** is illustrated in **Figure 1** that shows the DSBP5_0 distribution in Total, Therapy and Placebo.

For the NPT group, the total genotyping rate in remaining individuals was 99.67%; 6071 SNP failed the missingness test (call rate<90%) and 258148 SNPs had MAF<0.05. After frequency and genotyping pruning 848340 SNPs remained following filtering using MAF threshold of 0.05 (data not shown).

In view of the above, Applicants selected a cut off value for the QT DSBP5_0 of ≤ 11.7 mmHg, relative to the lowest tertile of the distribution of DSBP5_0 (-11.7 mmHg, that is, 33 out of 99 patients) to generate a binomial phenotype variable, the response–non response to the rosfuroxin. The DSBP5_0 threshold selection was performed to provide a parameter that is indicative of both statistical and clinical relevance of the results.

A graphic representation of the results of the descriptive statistical analysis showing the selected QT threshold is illustrated in **Figure 2**.

Figure 3 illustrates the genetic relatedness among the tested individuals detected using the top axis of variation showing a mild heterogeneous clusterization of individuals distributed around zero. The assessment (and correction) of population stratification is relevant to avoid the false positive and false negative significant associations due to the presence of systematic ancestry differences.

An inferential statistical analysis was then performed using the QT calculated to detect SNPs that are significantly associated to a different response to the treatment (placebo or active drug).

Table 3: Inferential Statistical Analysis

Procedure	Analysis	Selected Threshold
Univariate	<p>single point analysis of SNPS considered one by one assessment performed on the quantitative trait interaction test (G*E, Gene*Environment) as implemented in gPLINK [Ref 33]</p> <p>Relevant parameter P value of the SNP*therapy association</p>	<p><i>P</i> value <i>SNP*therapy</i> association $<10^{-4}$</p>

Table 3: Inferential Statistical Analysis

Procedure	Analysis	Selected Threshold
Interaction	<p>Interactions across tested genes analyzed to test dependence of QT phenotype variations on joint effect of SNPs</p> <p>Assessment performed using a single linear regression model, as implemented in StataSE 9.2,</p> <p>Parameter: delta DSBP5_0 between therapy and placebo</p>	<p>Identification only of SNPs (and their relative genotypes) that have the greatest delta DSBP5_0 between therapy and placebo choosing as cutoff a delta SBP5_0>15mmHg</p>

Table 3 summarizes the statistical procedures, thresholds and analysis selected by Applicants in view of the results of the descriptive statistical procedure.

In particular, with reference to the univariate analysis a single point analysis where the SNPs are considered one by one was performed. The quantitative trait interaction test (G*E, Gene*Environment) performed evaluates the association as

$$\text{Phenotype} = \text{SNP} + \text{therapy} + \text{SNP*therapy}$$

where the emphasis of the analysis was on the SNP*therapy component, i.e. in the interaction rather than in the main effects., since the main effect “therapy” corresponds to testing the clinical trials per se, without considering the genetic component. The main effect “SNP” looks for SNPs affecting variation in blood pressure without considering the modification induced by the therapy. Only the

interaction effect (G*T) evaluates which SNPs (G=gene) affect SBP in subjects receiving either the active drug or the placebo (T=Therapy).

A threshold of $p < 10^{-4}$ was selected to screen the most significant associations that could form a list of top SNPs. In particular, Applicants purposefully selected a
5 “conservative” p value (against False Negative) to screen out the less significant results [Ref. 34, 35]. Additionally, all potential positive associations have been meaningfully verified with at least two statistical programs (plink and stata). Results of univariate analysis performed according to the above approach are illustrated in **Figure 4** (see also Example 6 below).

10 With reference to the inferential interactions analysis, the interactions across various genes were tested to see if the observed variations of the QT phenotype DSBP5_0 depend on the joint effect of more SNPs considered together.

In particular, a single linear regression model, as implemented in StataSE 9.2, was then used to test for the interaction effect (SNP1*SNP2*ther) between a first set of
15 SNPs (SNP1) and a second set of SNPs (SNP2) in addition to the marginal effects of SNP1 and SNP2, within rostaduroxin/placebo.

The SNPs sets were established taking into account the genes where the SNPs were detected, and the possible involvement of the genes in mechanisms identified as responsible of the phenotype of choice (variation of blood pressure).

20 Those SNPs were further selected to identify the genotypes with the largest response to rostaduroxin compared to placebo by performing a Statistical ANOVA analysis using STATA software in placebo and rostaduroxin with DSBP5_0 as

dependent variable and the candidate significant SNPs as independent variables. In particular, to select the genotypes of the interactions between two SNPs with the largest response to rosiglitazone compared to placebo, the Applicants performed an ANOVA statistics in placebo and rosiglitazone with DSBP5_0 as dependent variable
5 and the interaction s between SNPs as independent variables. The Applicants report an example of this procedure in **Figure 5**: interaction between rs8899 and rs4678. The Applicants selected the interaction between the genotype AA of rs8899 and the genotype BB of rs4678 because it presents the greatest remarkable decrement in the therapy group and not in the placebo group.

10 In outcome of this investigation, the Applicants selected the genotypes of interactions of SNPs having a remarkable decrement of the QT phenotype DSBP5_0 in the rosiglitazone and not in the placebo group, such as the example of rs8899 and rs4678 in **Figure 5**.

All the genetic analyses were performed using the program package gPLINK [Ref.
15 33]. Principal Component Analysis (PCA) using the Eigensoft package (version 2.0 for Linux platform, Department of Genetics, Harvard Medical School, Boston, USA). Genomic inflation factor λ was calculated using Genomic Control (GC) of eigensoft package. To complete the statistical genetic analyses and for all those analyses beyond the pure statistical genetics approach, the program StataSE 9.2
20 was used. A skilled person will be able to identify all the additional details statistical analyses upon reading of the present disclosure.

Following the descriptive and inferential statistical analysis genotyping profiles were also created for the purpose of discriminating Responders (R) from Non-Responders (NR) to the active treatment using the smallest possible set of significant SNPs. In this case, a "genetic profile" is a linear combination of
5 genotypes at single SNPs or at their interactions.

To create the profiles different genotypes for each SNPs were considered as variable and in particular the homozygous less frequent genotype was identified as genotype 1 (g1), the heterozygous genotype was identified as genotype 2 (g2) and the homozygous more frequent genotype was identified as (g3).

10 Accordingly, genetic profiles were built that could have for example a g1 of an SNP1 (component 1), a g2 of an SNP2 (component 2) and the interaction of the g1 of SNP3 with the g2 of SNP4 (component 3) as factors. A profile can have any number of components.

Any given profile was coded equal to 1 if at least one component, presents the
15 significantly associated genotype (e.g., the g1 of SNP 1 in the example before), otherwise the profile is coded as 0. Then, all subjects are classified as 0 or 1, depending on their fit to the profile allowing a profile to characterize a defined subset of patients.

The predictive ability of different profiles to classify subjects into R or NR, i.e.
20 finding the genotypic profiles that discriminate R from NR for rostaduroxin, was then tested using a logistic regression performed to procedures such as the ones described in [Ref. 36, 37].

The parameter selected by Applicants to evaluate the genetic profiles was the Odds Ratio (OR) which is one of the parameters considered informative of performance of pharmacogenomic tests according to FDA guidelines [Ref. 38]. In particular, according to FDA guidelines, OR is a clinically relevant parameter for
5 evaluating the degree of discrimination according to the different genetic profiles between patient responders to the drug instead of placebo.

The OR value indicates the ratio of the odds in test positive patients (responders) to the odds in test negative patients (not responders) according to the defined genetic profile. The Odds ratio combines the Positive (PPV) and the Negative
10 (NPV) Predictive Values as follows: $PPV \times NPV / [(100-PPV) \times (100-NPV)]$. The Predictive values (either positive or negative) represent the proportion of patients with a positive or negative test result that have the clinical condition of interest (i.e. response to the drug with a defined genetic profile). In other word, OR is the probability of being a responders (PPV) or non responders (NPV) to the test. An
15 Odds ratio of 1 indicates that the test is non-informative, thus the higher the Odds ratio the higher is the predictive power of the test.

Based on the results of the above study, Applicants identified several SNPs and related genotypic profiles that significantly affect the selected quantitative phenotype for detecting the effect of rostaduroxin.

20 In particular, some core SNPs located in genes previously not associated with pathways affecting blood pressure surprisingly showed a remarkable ability to enhance the effects of rostaduroxin as illustrated in the following examples.

Example 1: core SNPs affect individual's response to rostaduroxin

In outcome of the above outlined study a group of SNPs was identified as significantly affecting the individuals' response to rostaduroxin that is herein also identified as core SNPs. The main features of the core SNPs herein described are

5 illustrated in the **Table 4**.

Table 4: Core SNPs

SNP ID	rs16877182	rs5013093	rs2461911	rs12513375	rs16893522	rs2345088
Chr	7	6	10	4	6	2
Major Allele	C	C	G	T	G	C
Minor Allele	T	T	A	G	A	T
P_GXE	2,89E-05	3,41E-05	4,43E-05	6,91E-05	8,54E-05	9,63E-05
position	11753617	29928565	57078480	148244380	82560511	18079898
GENE	THSD7A	Unknown	Unknown	Unknown	Unknown	unknown
Location	Intron	Intergenic	Intergenic	Intergenic	Intergenic	intergenic
nearest flanking gene(NFG)	N/A	HLA-G	LOC389970	TTC29	FAM46A	KCNS3
distance between SNP and NFG	N/A	21 kb-Flanking_3'	18 kb Flanking_3'	150 kb-flanking 5'	41 kb-Flanking_5'	102 kb Flanking_3'
protein name	Thrombospondin type-1 domain-containing protein 7A precursor.	HLA class I histocompatibility antigen. alpha chain G precursor	Pseudogene	TPR repeat protein 29	family with sequence similarity 46, member A	Potassium voltage-gated channel subfamily S member 3

The core SNPs rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375 are newly identified single nucleotide polymorphisms, with exact chromosomal location in human genome but, at present, with unknown function, that have been identified in a Genome-Wide Scanning and association analysis (GWAS) as the smallest set of significant SNPs associated to blood pressure response to rostaduroxin in outcome of the statistical analysis outlined above.

In particular these SNPs were identified following genotyping of the whole genome of the tested individuals performed according to Whole Genome Genotyping (WGG) based on the Sentrix BeadChip platform [Ref. 10]. More particularly, the WGG was performed using Human1M Duo CHIP - Infinium II Assay to interrogate over 1 million SNPs along the whole genome of the patients, through unrestricted locus selection according to procedure described identifiable by a skilled person and described, for example, in [Ref. 10, 11, 12] in further detail.

The SNPs detected in outcome of genotyping were first subjected to univariate analysis and then to further analysis to select the SNPs genotypes with the largest response to rostaduroxin as illustrated above.

In particular, to select the genotypes with the largest response to rostaduroxin compared to placebo, the Applicants performed an ANOVA statistics (oneway) in placebo and rostaduroxin with DSBP5_0 as dependent variable and the significant SNPs as independent variables.

The analysis performed is exemplified in **Figure 6** where an analysis for SNP rs2461911 is shown that concerns a significant phenotype variance in the SNP

genotypes g1, g2 and g3 greater in therapy group ($p=0.002$) than in placebo ($p=0.045$).

Variation of the DSBP5_0 values for the three genotypes of SNP rs2461911 g1, g2 and g3 is also illustrated in **Figure 7**, which shows the plot of the DSBP5_0 values for the three genotypes of SNP rs2461911 comparing rostaduroxin and placebo groups. From the illustration of **Figure 7**, it is clear that in genotype 1 there is a clear reduction of blood pressure with rostaduroxin while with placebo the blood pressure is modestly increased. Conversely in genotype 3 the blood pressure fall seems to be greater with placebo. What it is important is the direction of changes in blood pressure response with placebo and rostaduroxin according to these genotypes that clearly follow and opposite trend. This can be analyzed and we can establish the statistical significance of the model and of the interactions between rostaduroxin and placebo for that particular SNP. An appropriate statistical analysis provides the significance of the interaction (which is accepted only if the significance of the model is < 0.05). The p values for interaction are given in table 4 as P-GXE.

A similar approach was applied to analyze and select the other core SNPs so that in outcome of this investigation, the Applicants selected the genotypes of SNPs having a remarkable decrement of the QT phenotype DSBP5_0 in the rostaduroxin and not in the placebo group, such as the example rs2461911 in **Figure 7**.

A summary of the data related to DSBP5_0 in individuals presenting the core SNPs and treated with rostaduroxin (Therapy) versus the individuals presenting the core SNPs and treated with placebo (Placebo) is illustrated in **Table 5**.

Table 5: Decrement in DSBP5_0 for Core SNPs

SNP ID	p_value ANOVA	Illumina genotype	Relevant genotype	DSBP5_0 Therapy	DSBP5_0 Placebo	Delta DSBP5_0
rs2345088	0.0002	1	TT	-30.5	3.43	33.93,
rs16877182	0.0003	2	C/T	-21.67	-2.82	18.85,
rs16893522	0.0048	1	AA	-22.43	4.60	27.03,
rs2461911	0.0022	1	AA	-20.6	2.22	22.82,
rs5013093	0.0022	1	TT	-20.49	1.60	22.09,
rs12513375	0.0024	3	TT	-19.18	-3.25	15.93,

In particular, the data in **Table 5** were obtained using a stepwise linear regression using DSBP5_0 as dependent variable and the SNPs as independent variables to select the SNPs significantly associated to the QT phenotype DSBP5_0.

Example 2: A genetic profile comprising core SNPs affect individual Response to rostaduroxin

Following the identification of the SNPs, Applicants investigated the predictive ability of genetic profiles comprising the core SNPs of Example 1 were considered. The rationale supporting construction of genetic profiles relies upon the well established notion that the phenotypic effect of a given SNP must also be evaluated within the context of the other SNPs harbored on genes coding for proteins that interact with the protein associated to the first SNPs (genetic network). In this sense, a network analysis also implies the concept of genetic

epistasis [Ref 39]. In fact, alleles at two loci may not have any detectable effect when these alleles are analyzed separately but they may become phenotypically relevant when analyzed together, since they co-occur in the same subjects.

The Applicants evaluated if a genetic profile comprising core SNPs in the therapy group only, can discriminate the Responders from Not Responders to the treatment using as a predictive model a logistic regression in which the dependent variable is the dicotomic phenotype (R or NR) and the independent variable the specific profile. The applicants then evaluated the goodness of the model calculating the predictive parameters (Odds Ratio, PPV, NPV).

Exemplary data related to the genetic profile including all core SNPs of Example 1 are illustrated in **Figure 8**. In particular, **Figure 8** illustrates data concerning Odds Ratio (OR) and predictive values (p-values) for profiles comprising the core SNPs, which are parameters considered informative of performance of pharmacogenomic test according to the FDA guidelines [Ref.38].

In particular, the OR value indicates the ratio of the odds in test positive patients (responders) to the odds in test negative patients (not responders) according to the defined genetic profile. In particular, the Odds ratio combines the Positive (PPV) and the Negative (NPV) Predictive Values as follows: $PPV \times NPV / [(100 - PPV) \times (100 - NPV)]$. In other words, OR is the probability of being a responder (PPV) or non responders (NPV) to the test. An Odds ratio of 1 indicates that the test is non-informative, thus the higher the Odds ratio the higher is the predictive power of the test. The p-values (either positive or negative) represent the proportion of patients

with a positive or negative test result that have the clinical condition of interest (i.e. response to the drug with a defined genetic profile).

The p-value parameter is calculated based on the zscore and it indicates the significance of OR. The zscore parameter indicates: $\ln(\text{OR}) / \text{Standard Error}(\ln\text{OR})$. The zscore has a negative value if the OR is minor to 1 and then if the profile is not able to predict the response to drug. While the zscore has a positive value if the $\text{OR} > 1$ and then the profile is able to predict the response to drug: if zscore is high the OR is more significant due to the smaller variance.

Among the above mentioned parameters, the Odds Ratio (OR) is considered clinically relevant for evaluating the degree of discrimination according to the different genetic profiles between patient responders to rosfuroxin instead of placebo [Ref.38].

The data related to a profile comprising all core SNPs (Profile 4) summarized in **Figure 8** were obtained considering data from patients including one or more SNPs of the core SNPs listed in the profile. The criteria is justified by the occurrence of the two factors that usually support inclusion of patients carrying at least one SNP in a single unique profile: i) the strong prediction power of the SNP and ii) by a common plausible biological mechanism that link the SNPs at issue. In particular, the prediction power of the SNPs may be evaluated from the OR and the correctly classified patients according to methods identifiable by a skilled person. The corresponding parameter is a “correctly” value that for patients with profile 4 is of 79.8% (see **Figure 8**). This value indicates that in 80 patients out of 100 the

profile provides a correct classification of patients into responders and non responders.

In view of the above results, it is possible to conclude that the core SNPs affect the pharmacological activity of rosfuroxin with clinical relevance. In particular, the clinical relevance is due to the magnitude of the blood pressure drop difference between drug (rosfuroxin) and placebo, which ranges from 23 to 15 mmHg with rosfuroxin while, according to literature, this difference ranges between 4 and 6 mmHg with the ARBs.

Preliminary data in patients carrying the profile 4 obtained in two separate studies demonstrate that the drop in blood pressure obtained with rosfuroxin is more than 40% larger than that detected among the available antihypertensive agents (see **Figure 8**, bottom portion). In particular, individuals carrying profile 4 show a modification in blood pressure of: - 12.3±1.5 mmHg with HCTZ; -11.3± 1.7 with Losartan and -18.74 ±1.8 mmHg with rosfuroxin; individuals with profile 8 show the a decrease in blood pressure of - 11.3± 1.2 with HCTZ; -11.6± 1.3 with Losartan and - 15.2±1.5 mmHg with rosfuroxin; individuals with profile 9 show the a decrease in blood pressure of -11.9 ±1.2 with HCTZ; -11.4 ± 1.4 with Losartan and - 15.2±1.5 mmHg with rosfuroxin.

Example 3: A genetic profile including core SNPs together with relevant SNPs affects response to rosfuroxin

Interactions of the core SNPs with additional SNPs identified in the course of the above mentioned pharmacogenomic study were analyzed to verify the possible

identification of additional genetic profiles suitable to discriminate R from the NR to the treatment using as a predictive model a logistic regression.

In particular the core SNPs profile of Example 2 (Profile 4) was combined with additional relevant SNPs identified in the course of the study.

5 Relevant SNPs, in the context of the present description indicate SNPs suitable to discriminate Responders from Non-Responders to rostafuroxin.

In particular, relevant SNPs were first investigated in the following three groups of genes: a) genes that are directly involved in the action mechanisms of rostafuroxin (such as Adducin and EO genes – see Example 4) herein also indicated as CAND

10 1; b) genes that may be involved in the development of hypertension and/or in an organ damage associated to hypertension (such as WNK – see Example 5) herein also indicated as CAND 2; and c) genes identified by performing a whole genome scanning (such as HLA-A, see Example 6) herein also indicated as GWS.

In particular, SNPs in those genes were first identified by genotyping the selected
15 genes. Relevant SNPs were then selected by subjecting the detected SNPs to descriptive and inferential analysis as further illustrated in Examples 4 to 6.

The relevant SNPs so identified were then grouped in genetic profiles together with the core SNPs of profile 4 of Example 2.

The results show that genetic profiles comprising core SNPs and relevant SNPs
20 are even more effective in discriminating rostafuroxin Responders from Non-Responders as illustrated in **Figure 8**.

In particular, in the summary of **Figure 8** the OR and p-value and DSBP5_0 detected for additional profiles formed by the core SNPs (profile 4) and additional CAND 1, CAND 2 and/or GWS SNPs are also illustrated (see in particular profile 8 and profile 9 of **Figure 8**). From the analysis of the data of **Figure 8** it appears that

5 by including additional SNPs in the profiles, the OR values and “correctly” value are increased with respect to the ones of the profile 4 (see profile 8 and profile 9 in **Figure 8**). Also the inclusion of those SNPS determines an increase in the size of the target population from the 26% of total population of profile 4 to 44% of the total population of profile 9.

10 A possible explanation of the synergic effect between the core SNPs and the additional SNPs indicated in **Figure 8**, herein provided for the purpose of guidance and not intended to be limiting, is the inclusion of the SNPs at issue in a same genetic network underlying complex diseases such as hypertension. The experimental evidence obtained by the Applicants supports the conclusion that

15 these SNPs can either interfere with or modulate the other genes (such as CAND1 or CAND2 already associated with pathways affecting blood pressure - see Examples 4 and 5) in a genetic networking or affect other genes which may be unrelated to a priori selected list of candidates (see profile 4 in comparison with profiles 8 and 9).

20 Accordingly, a possible explanation of the data reported herein is that the discriminatory capacity of the core SNPs (profile 4) is increased by the CAND 1 and 2 because of inclusion in a same genetic network that combines/integrates the

effects of GWS, Core SNPs, CAND 1, CAND 2 and additional unknown SNPs which are comprised in the network(s).

The increase of the discriminatory capacity and of the size of the selected patients included in the profile that has been achieved by moving from profile 4 to profile 9, 5 supports the network concept.

Specific genotypes for the additional relevant genes included in profiles 8 and 9 of **Figure 8** are further described in **Table 6** and **Table 7** below.

Table 6: Profile 8 and Profile9 SNPs

SNP name	SNP ID	chr	Major Allele	Minor Allele	position	GENE	Location	protein name
ADD1	rs4961	4	G	T	2876505	ADD1	Exon (missense G460W)	adducin alpha subunit
ADD2	rs4984	2	C	T	70753911	ADD2	Exon (silent)	adducin beta subunit
HSD18	rs10923835	1	A	T	119811854	HSD3B1	Intergenic	3-beta-hydroxysteroid dehydrogenase
HSD19	rs947130	1	G	A	119818255	HSD3B1	Intergenic	3-beta-hydroxysteroid dehydrogenase
LSS2	rs914247	21	G	A	46434105	LSS	3' UTR	lanosterol synthase
MDR2	rs1045642	7	T	C	86976591	MDR1(A BCB1)	Exon (silent)	Multidrug resistance 1 (ATP-binding cassette, subfamily B, member1)
WNK1	rs880054	12	A	G	858819	WNK1	Intron	WNK lysine deficient protein kinase1
rs10502933	rs10502933	18	C	T	47548901	unknown	Intergenic	
rs2131127	rs2131127	3	C	T	149906833	AGTR1	Intron	angiotensin II receptor type 1
rs4309483	rs4309483	18	C	A	54236897	LOC100134069	Unknown	Hypotetical protein LOC100134069 (3' flanking to NEDD4L)
rs4739037	rs4739037	8	G	A	64065878	NKAIN3	3' UTR	Na ⁺ /K ⁺ transporting ATPase interacting 3

Table 7: Interactions between candidate and top SNPs in Profile 8 and Profile 9

SNP 1	SNP1 ID	relevant SNP1 genotype	SNP1 allele	SNP 2	SNP2 ID	relevant SNP2 genotype	SNP2 allele	DSB50 PLAC EBO	DSBP50 ROSTAF UROXIN	Delta Rosta _plac ebo
MDR2	rs1045642	TT	T major	HSD18	rs10923835	AT+TT	T minor	-.0.10	-.17.40	17.30
LSS2	rs914247	GA+AA	A minor	MDR2	rs1045642	CC	C minor	-.3.95	-.16.91	12.96
LSS2	rs914247	AA	A minor	ADD1	rs4961	GT+TT	T minor	5.17	-.22.32	27.49
HSD19	rs947130	GG	G major	NEDD4L	rs4309483	AA	A minor	10.3	-.17.85	28.15
MDR2	rs1045642	TT	T major	AGTR1	rs2131127	CC	C major	-.2.55	-.16.9	14.34
ADD2	rs4984	CC	C major	TOP	rs10502933	CT	C major	5.52	-.19.21	24.73
LSS2	rs914247	AA min	A minor	WNK1	rs880054	AG+GG min	G minor	0,48	-.16	16,48
HSD19	rs947130	GG	G major	NKAIN3	rs4739037	GA	G major	-.2.46	-.18.18	15.72

In view of the above results, it is possible to conclude that core SNPs comprised in a profile together with additional SNPs affect the pharmacological activity of rostafuroxin with clinical relevance which can be even higher than the activity of the core SNPs alone.

Example 4: Relevant SNPs affecting response to rostafuroxin: CAND 1 genes

Applicants investigated inclusion of additional relevant SNPs in genetic profiles also including the core SNPs of example 1 that identify responders to rostafuroxin.

10 In a first series of experiments, SNPs of genes involved directly in the mechanisms of action of rostafuroxin (herein also identified as CAND 1 genes) were investigated.

In particular, CAND 1 genes that were investigated included genes coding for adducin subunits (ADD1, ADD2, ADD3), and genes involved in the EO synthesis and metabolism (CYP11A1, HSD3B1, LSS, ABCB1/MDR1 and SLCO4C1). A summary of the features of the investigated genes is reported in **Table 8**.

5

Table 8. Selected Candidate Genes (CAND 1)

N	Gene Symbol	Chr	Gene name
2	ADD1	4	alpha adducing
3	ADD2	2	beta adducing
4	ADD3	10	gamma adducing
5	CYP11A1	15	cytochrome P450, family 11, subfamily A, polypeptide 1 (cholesterol monooxygenase side-chain cleaving)
6	HSD3B1	1	hydroxy-delta-5-steroid dehydrogenase, 3 beta-and steroid delta-isomerase 1
7	LSS	21	lanosterol synthase (2.3-oxidosqualene-lanosterol cyclase)
1	ABCB1/MDR1	7	ATP-binding cassette, sub-family B (MDR/TAP), member 1
8	SLCO4C1	5	solute carrier organic anion transporter family, member 4C1

In particular, **Table 8** shows the selected CAND 1 genes and the related chromosome location, gene symbol and Gene name.

For each CAND1 gene of **Table 8**, SNPs were detected using SNPs: Single SNP

10 analysis with Taqman Assay (assay on demand or custom MGB with probe and primer design from ABI).

The detected SNPs were subject to univariate analysis and relevant CAND1 SNPs were selected on the basis of the detected a variation of the QT phenotype DSBP5_0 selected for the study.

Exemplary relevant CAND 1 SNPs are reported in **Table 9** and **Table 10** together with the related GXT association results. A significant p_GXT indicates a significant DSBP5_0 different response to the treatment (rostafuroxin/placebo).

Table 9: CAND 1 SNPs

SNP ID	GENE	CHR	Major Allele	Minor Allele	SNP position	Gene position	SNP location	p_value
rs4961	ADD1	4	G	T	2876505		exon (missense G460W)	Ns
rs4984	ADD2	2	C	T	7075391 1		exon (silent)	Ns
rs3731566	ADD3	10	A	G	1118760 79		Intron	Ns
rs914247 (LSS2)	LSS	21	G	A	4643410 5		3UTR	0.0027
rs1045642 (MDR2)	MDR1	7	T	C	8697659 1		exon (silent)	Ns
Various	HSD3B1	1				11985527 6		Ns
various	CYP11A1	15				72432145		Ns
various	SLCO4C1	5				10162887 1		Ns

Table 10: CAND 1 SNPs

SNP ID	p_value ANOVA	Relevant genotype	DSBP5_0 Therapy	DSBP5_0 Placebo	Delta DSBP5_0
rs914247 (LSS2)	0.0002	AA	-17	-6,16	10,87,

10

In particular, **Table 9** shows the results of the univariate analysis of selected exemplary CAND 1 SNPs together with related gene symbol, chromosome location, position on chromosome, location on gene and p value.

The two relevant SNPs for HSD3B1 gene (HSD18 and HSD19) are described in detail in **Table 6** and their relevance in **Table 7**.

In **Table 10** the data for the relevant SNP rs 914247 are reported.

As explained in the detailed description genes and adducin the genes included in table 9 are those suggested to encode adducin and enzymes involved in EO synthesis and transport. Rostafuroxin at picomolar concentrations “in vitro” or at nanomoles doses in animals is able to selectively correct the effect of mutated adducin or ouabain on Na-K Pump and cSrc, without blocking the effect of wild adducin.

10 **Example 5: Relevant SNPs affecting response to rostafuroxin CAND 2 genes**

In a second series of experiments, SNPs of genes that may be involved in the development of hypertension and/or in an organ damage associated to hypertension (herein also identified as CAND 2 genes) were investigated.

In particular, a larger set of genes that are pathophysiologically relevant were selected as CAND 2 genes. The selection criteria mainly included genes coding for the RAA enzymes and receptors, various families of ionic channels and transporters regulating renal sodium reabsorption, adrenergic receptors, podocyte proteins and transcription factors. The resulting set of genes is summarized in the illustration of **Figure 9**.

20 In particular, in **Figure 9** the Selected Candidate Genes "CAND2 together with the relevant chromosome location, gene symbol and Gene name are indicated.

Additional information concerning those genes is identifiable to a skilled person upon reading of the present disclosure.

For each CAND2 gene of the table of **Figure 9**, SNPs were detected using Tag SNPs present all over the genome and in the Illumina chip that could provide the evaluation of the variation within candidate genes to evaluate the influence of these genes on the blood pressure response to rostaduroxin.

The detected SNPs were subject to univariate analysis and only SNPs with a p-value GXT ranging from $1.78 \cdot 10^{-4}$ (rs7117314) to $5 \cdot 10^{-2}$ (rs945403) were selected with the same methodology illustrated for the selection of Core SNPs. Dealing with candidate genes we only used as a threshold a $p < 0.05$ instead of $p < 0.0001$ in view of previous data supporting the choice of candidate genes.

In particular the relevant CAND2 SNPs were selected on the basis of the detected a variation of the QT phenotype DSBP5_0.

Exemplary CAND 2 SNPs are reported in **Table 11**, together with the related GXT association results. A significant p_GXE indicates a significant DSBP5_0 different response to the treatment (rostafuroxin/placebo).

Table 11: Univariate analysis of relevant CAND 2 SNPs

N	Snps	gene_name	CHR	Position	P_GXE	Location
	rs242093	ACTN1	14	68551096	0,007169	flanking_5U TR
2	rs1996396	ADRA1A	8	26918290	0,002707	flanking_5U TR
3	rs10503806	ADRA1A	8	26938920	0,00381	flanking_5U TR
4	rs13251780	ADRA1A	8	26950888	0,004704	flanking_5U TR

Table 11: Univariate analysis of relevant CAND 2 SNPs

N	Snps	gene_name	CHR	Position	P_GXE	Location
5	rs17430706	ADRA1A	8	26894087	0,007211	flanking_5U TR
6	rs10102024	ADRA1A	8	26841288	0,009325	flanking_5U TR
7	rs526302	ADRA1A	8	26746612	0,01782	Intron
8	rs544104	ADRA1A	8	26767907	0,03642	Intron
9	rs3102087	ADRA1A	8	26755854	0,04356	Intron
10	rs5183	AGTR1	3	149942574	0,02	Coding
11	rs3772627	AGTR1	3	149912944	0,04049	Intron
12	rs2276736	AGTR1	3	149908563	0,04824	Intron
13	rs2131127	AGTR1	3	149906833	0,04983	Intron
14	rs3741559	AQP2	12	48631243	0,03534	Intron
15	rs2217342	ATP1A3	19	47181356	0,008238	Coding
16	rs10927888	CLCNKA	1	16226098	0,04384	Intron
17	rs6604909	CLCNKB	1	16244519	0,03099	Intron
18	rs945403	CLCNKB	1	16246917	0,04996	Intron
19	rs7117314	FXD2	11	117203972	0,0001782	5UTR
20	rs10790212	FXD2	11	117207900	0,001169	flanking_5U TR
21	rs11216598	FXD6	11	117253662	0,00677	flanking_5U TR
22	rs910682	FYN	6	112282428	0,0004279	flanking_5U TR
23	rs13218316	FYN	6	112189727	0,00389	Intron
24	rs4309483	NEDD4L	18	54236897	0,006163	flanking_3U TR
25	rs13280307	NKAIN3	8	63586548	0,001652	Intron
26	rs4739037	NKAIN3	8	64065878	0,002954	UTR
27	rs17596774	PKD1	16	2086474	0,04037	Intron
28	rs2728108	PKD2	4	89180760	0,006608	Intron
29	rs17786456	PKD2	4	89176586	0,03221	Intron
30	rs7696304	PKD2	4	89179022	0,03269	Intron
31	rs2725222	PKD2	4	89177516	0,03857	Intron
32	rs17199565	SCNN1B	16	23181205	0,004757	flanking_5U TR
33	rs2758152	SGK1	6	134530606	0,008541	flanking_3U TR
34	rs1057293	SGK1	6	134535090	0,04496	Coding

Table 11: Univariate analysis of relevant CAND 2 SNPs

N	Snp	gene_name	CHR	Position	P_GXE	Location
35	rs16960712	SLC12A1	15	46329907	0,01024	Intron
36	rs759359	SLC8A1	2	40182609	0,007413	flanking_3U TR
37	rs404214	SLC8A1	2	40307852	0,02053	Intron
38	rs1005213	SLC8A1	2	40245293	0,0303	Intron
39	rs17025453	SLC8A1	2	40259918	0,03507	Intron
40	rs2110923	SLC8A1	2	40211501	0,04026	Intron
41	rs1428571	SLC8A1	2	40243974	0,04325	Intron
42	rs435404	SLC8A1	2	40293896	0,04652	Intron
43	rs12908787	TJP1	15	27878217	0,003622	Intron
44	rs11647727	UMOD	16	20263666	0,0089	Intron
45	rs880054	WNK1	12	2594827	0.03876	Intron
46	rs11064584	WNK1	12	866932	0,04682	Intron

In particular, in **Table 11** the GXT association results for placebo and therapy is illustrated. A significant p_GXT indicates a significant DSBP5_0 different response to the treatment (rostafuroxin/placebo).

5 Example 6: Relevant SNPs affecting response to rostafuroxin: GWS genes

In a third series of experiments, SNPs of genes detected with Whole Genome scanning (herein also identified as GWS genes) were also investigated.

Genomic SNPs were genotyped with the Human1M array from Illumina using Human1M Duo CHIP genotyping Bead Chip according to procedure described in
 10 [Ref. 10, 11, 12]. In particular, In total, 1111190 (92.66 % of the total) SNPs were analyzed because the SNPs of chromosomes X and Y as well as the SNPs (XY) of pseudo-autosomal region of X were not considered.

The detected SNPs were subjected to univariate analysis in an approach to identify relevant SNPs according to methodologies described in the examples section.

The results of the univariate analysis (Quantitative trait Interaction – GxE) for GWS genes are illustrated in **Figure 4**, which shows results for 848340 SNPs genotyped
5 in a sample from 193 NPT Patients with the 107 SNPs having a p value lower than the established threshold of $p < 10^{-4}$ are shown as dots.

A detailed annotation was then performed of the identified 107 SNPs aimed to clarify the role of the specific genomic region interested in association. The 107 top SNPs identified from this GWAS are actually denoted by these genomic positions:
10 7 in coding regions, 4 in 3'UTR, 30 in introns and 66 in intergenic regions. Among the last-mentioned group, some SNPs are proximal to gene region and could be localized into the relative promoter, while some others are so far from an annotated gene to be considered in desert regions.

Therefore, a more detailed annotation has been performed for top SNPs included
15 in Profile 4 (single topSNPs) and for Profile 5 (interacting topSNPs) only, and we observed that the majority of them are intergenic variants with a minimum set of intronic SNPs. All these variants may belong to so-called “junk DNA” regions [Ref. 40], as already mentioned in Introduction - paragraph 1.3, thus representing a rich substrate for evolutionary innovations of sequences in eukaryotes.

20 The procedure followed for exhaustive annotation took in account for: *i.* SNPs showing MAF >5%; *ii.* a more recent mapping with help of different databases (NCBI Entrez Gene, HapMap, Ensembl); *iii.* selection from a group of SNPs in

perfect or strong LD among them, with possible location in genic or functional regions; *iv.* PubMed analysis; *v.* annotation of published miRNA sequences and relative genomic targets.

For intragenic SNPs, Applicants noted no coding or splicing variants but we
5 identified common intronic polymorphisms located in genes whose function is often unknown. Two topSNPs (rs3893464 and rs 5013093) were placed within the major histocompatibility complex class I region on chromosome 6, a peculiar region of extensive and high LD which contains several genes. In this case, an accurate gene annotation is more complex, and the expression and functional pattern
10 investigation of included genes could help to define the right region. As SNPs can have different effects also on the miRNA target composition, especially for 3'UTRs, all topSNPs were virtually tested in different databases (www.patrocles.org, microrna.sanger.ac.uk, www.microrna.org), but any interesting results returned. Applicants also considered a searching against the intact precursor sequences or
15 just the mature miRNAs. However, marker identification of drug response for the purposes of prediction, without further genetic localization of the source of the signal would be a sufficient endpoint for a GWA study.

Following the above characterization, the initial 107 GWS SNPs were further selected to identify the genotypes with the largest response to rostaduroxin
20 compared to placebo by performing a Statistical ANOVA analysis using STATA software in placebo and rostaduroxin with DSBP5_0 as dependent variable and the

107 significant SNPs as independent variables. Additionally with this analysis the relevance of the genotype of above mentioned SNPs was also analyzed.

With this approach eventually only 35 SNPs (and their relative genotypes) were selected that have a DSBP5_0 decrement in the therapy and not in the placebo group to be considered as relevant GWS. A list of the relevant GWS gene is summarized in **Table 12**.

Table 12: Univariate analysis of relevant GWS SNPs

SNPs				THERAPY			PLACEBO			DELTA
rs SNP	Gene	p_value ANOVA	genotype	DSBP5_0 therapy	SD	number of patients	DSBP5_0 placebo	SD	No. of patients	delta_Therapy_placebo
rs12996186	ARL5A	0.0001	2	-22.785714	16.342626	7	-4.8222221	11.005428	9	17.9634919
rs9893372	ATP2A3	0.0002	3	-10.910638	12.081035	47	-6.4765957	10.579003	47	4.4340423
rs7216331	COX10	0.0023	2	-15.808333	1.150387	12	-1.8944444	9.5719856	18	13.9138886
rs7521668	DPH5	0.0004	1	-25	0	1	3.95	6.5760933	2	28.95
			2	-13.044	12.951707	25	-6.0227273	9.8237774	22	7.0212727
rs188334	FAIM3	0.0036	1	-11.819048	10.627776	21	-3.6727274	13.932941	22	8.1463206
rs4998662	FAM46A	0.0001	2	-15.805556	1.151048	18	-2.2666667	7.1477936	15	13.5388893
rs16893522	FAM46A	0.0048	1	-22.433333	14.654805	3	4.6000002	5.6568545	2	27.0333332
			2	-1.138125	11.911463	16	-4.0117647	12.26524	17	2.8736397
rs6457110	HCG9	0.0023	1	-10.351613	12.372035	31	-4.4896552	11.787019	29	5.8619578
rs3893464	HCG9	0.0086	1	-10.989474	13.815245	19	-1.9736842	8.6017337	19	9.0157898

Table 12: Univariate analysis of relevant GWS SNPs

SNPs				THERAPY			PLACEBO			DELTA
rs SNP	Gene	p_value ANOVA	genotype	DSBP5_0 therapy	SD	number of patients	DSBP5_0 placebo	SD	No. of patients	delta_Therapy_placebo
rs2517718	HLA-A	0.0006	1	-11.825806	11.503274	31	-5.6137931	10.594464	29	6.2120129
rs1362126	HLA-F	0.0037	3	-10.294118	10.867241	34	-5.3636363	11.464342	33	4.9304817
rs5013093	HLA-G	0.0022	1	-20.485714	10.724182	7	1.5999999	2.8284271	2	22.0857139
rs2345088	KCNS3	0.0002	1	-30.5	96.166511	2	3.4333334	11.033736	3	33.9333334
			2	-10.693103	11.909148	29	-7.1814815	8.3223072	27	3.5116215
rs6718282	KCNS3	0.0028	1	-41.299999		1	/	/	0	
			2	-12.625	82.536465	8	1.2	12.445381	9	13.825
rs721207	LOC131691	0.0032	3	-11.584375	13.303943	32	-4.65	11.612437	24	6.934375
rs2555500	LOC389174	0.003	1	-10.517391	1.221436	23	-5.3172413	10.152799	29	5.2001497
rs2461911	LOC389970	0.0022	1	-20.6	1.267024	5	2.2166667	10.168268	6	22.8166667
rs8179654	LOC642727	0.0032	3	-10.953846	14.821472	13	-2.5117647	10.327686	17	8.4420813
rs1901139	LOC644192	0.0036	3	-12.107143	15.748087	14	-1.59	8.9522746	10	10.517143
rs2427832	LOC649458	0.0014	2	-10.384091	13.154536	44	-3.5387096	9.5961685	31	6.8453814
rs9361863	LOC728360	0.0013	1	-15	98.994949	2	4.6000002	5.6568545	2	19.6000002
			2	-13.477273	12.989.443	22	-4.6444444	12.13712	18	8.8328286
rs1998394	LOC728316	0.0074	3	-10.51282	1.334078	39	-4.725	11.632855	44	5.78782
ga001619	PIGR	0.0004	1	-13.615	97.036224	20	-4.363158	14.582418	19	9.251842
rs2275531	PIGR	0.0024	3	-12.18	1.063176	20	-4.363158	14.582418	19	7.816842
rs748140	PIGR	0.0034	1	-11.279167	1.179624	24	-4.7727273	13.75234	22	6.5064397
rs4710592	RCADH5	0.0033	3	-23.825	12.273107	4	-3.75	12.094548	14	20.075
rs2743951	RP3-377H14.5	0.0015	3	-11.169697	10.505638	33	-5.5499999	11.596885	32	5.6196971
rs10159569	SH3PXD2A	0.0013	1	-13.169231	13.134071	26	-2.5413793	8.8390981	29	10.6278517
rs3087816	SLC30A7	0.0004	2	-13.044	12.951707	25	-6.0227273	9.8237774	22	7.0212727
rs10493940	SLC30A7	0.0003	2	-12.132258	1.197376	31	-6.1826087	9.6284924	23	5.9496493
			3	-25	0	1	3.9500002	6.5760933	2	28.9500002
rs16877182	THSD7A	0.0003	2	-21.671428	93.414332	7	-2.81875	13.817295	16	18.852678

Table 12: Univariate analysis of relevant GWS SNPs

SNPs				THERAPY			PLACEBO			DELTA
rs SNP	Gene	p_value ANOVA	genotype	DSBP5_0 therapy	SD	number of patients	DSBP5_0 placebo	SD	No. of patients	delta_Therapy_placebo
rs2326912	TMEM200A	0.0008	1	-11.7	0	1	/	/	0	
rs1110446	TRIM31	0.003	1	-16.366667	77.860986	3	4.2249999	3.4451657	4	20.5916669
			2	-10.134211	14.101299	38	-6.6103448	12.376024	29	3.54
rs12513375	TTC29	0.0024	3	-19.177778	13.342392	9	-3.25	4.8086232	8	15.927778
rs17414954	VCAM1	0.0003	2	-13.030769	1.203637	26	-5.8727273	9.7369782	2	7.1580417

Example 7: Genetic Variations in Linkage disequilibrium with core SNPs

Even if the DNA variations included in profile 4, 8 and 9 have a strong genetic power in predict the Responder patients, they do not exhaust all the genetic variability having the best discriminatory capacity. According to Linkage Disequilibrium concept, a DNA variation (tag SNP) can be generally represented by a variable number of proxy SNPs able to type the variation equally or similarly compare to the tag SNP. Therefore, several additional genetic variations are included in the scope of the methods and systems herein described. Exemplary genetic variations in linkage disequilibrium with SNPs affecting the biological activity of rosfuroxin are listed in **Table 13**.

Table 13 Proxy SNPs relative to Core SNPs, Profile 8 and Profile9 SNPs, according to CEU HapMap data Rel 24

SNP name	SNP ID	chr	proxy SNPs (r2 0.9-1)	Tag window
rs16877182	rs16877182	7	rs7341453, rs10499404, rs10499406, rs6957230, rs17165141, rs16877173, rs16877184, rs10499401, rs17165148, rs17165136	1Mb

Table 13 Proxy SNPs relative to Core SNPs, Profile 8 and Profile9 SNPs, according to CEU HapMap data Rel 24

SNP name	SNP ID	chr	proxy SNPs (r2 0.9-1)	Tag window
rs5013093	rs5013093	6	rs2517861, rs2734981, rs2734984, rs9258606, rs2508051, rs2517870, rs9258610, rs1632882, rs3128910, rs2734985, rs5013088, rs35332866, rs2734980, rs5013087, ,rs2517860, rs2517850, rs1317834, rs2523760, rs5013091, rs1613062, rs7451408, rs9258690, rs2247719	750 kb
rs2461911	rs2461911	10	rs2461899	750 kb
rs12513375	rs12513375	4	rs6844319, rs11735165, rs11722430, rs4543091	750 kb
rs16893522	rs16893522	6	rs9449367, rs17730252, rs17662598, rs10081038, rs9449368	750 kb
rs2345088	rs2345088	2	no proxies in CEU HapMap	750 kb
ADD1	rs4961	4	rs1263345, rs2239728, rs1263347, rs4690001, rs4690000, rs4964, rs16843523, rs2285084, rs2237004	750 kb
ADD2	rs4984	2	rs740389, rs740388, rs7559120, rs740391, rs740387, rs1048747, rs11894520, rs6750771, rs740390, rs7559225	750 kb
HSD18	rs10923835	1	no proxies in CEU HapMap	750 kb
HSD19	rs947130	1	no proxies in CEU HapMap	750 kb
LSS2	rs914247	21	rs7282841, rs2839141, rs6518278, rs4819216, rs2839157, rs2280955, rs2839146, rs2254524, rs9717, rs999691, rs2839175, rs4818828, rs4819214, rs2330408	750 kb
MDR2	rs1045642 *	7	rs4437575, rs2235048	750 kb
WNK1	rs880054 *	12	no proxies in our population, no info in CEU HapMap	750 kb
rs10502933	rs10502933	18	rs12605208, rs3851123, rs10502932, rs17752711, rs12604658, rs1552090, rs2045748, rs8097074, rs17752681, rs1531686, rs12605843, rs12606532, rs17752449, rs17752602, rs17752743	1Mb
rs2131127	rs2131127	3	rs10935724, rs12695877	750 kb
rs4309483	rs4309483	18	rs9319930, rs11152071, rs3744868, rs4384676, rs4383234, rs7226817, rs8099014, rs7230036, rs4940711, rs4464160, rs4940393, rs6566970, rs9319929, rs11152077, rs4940697, rs17064977, rs4245268, rs4640266, rs7234602, rs4331413, rs4559989, rs4940701, rs4245271, rs6566972, rs11152073, rs4940698, rs1806761, rs8092072	750 kb

Table 13 Proxy SNPs relative to Core SNPs, Profile 8 and Profile9 SNPs, according to CEU HapMap data Rel 24

SNP name	SNP ID	chr	proxy SNPs (r2 0.9-1)	Tag window
rs4739037	rs4739037	8	rs12542042, rs4739011, rs12541993, rs10957266, rs10464903, rs12549172, rs12681795, rs12543961, rs10464905, rs930840, rs12546361, rs4739047, rs4737629, rs3758147, rs12542282, rs12541047, rs10957270, rs10957269, rs4739046, rs12545230, rs9969662, rs10957272, rs4737627, rs10464904, rs10957261, rs12548172, rs12547772, rs10957268, rs12678214, rs1480115, rs16929963, rs12676348, rs10957248, rs10957265, rs16929988, rs10957260, rs4739028, rs7818582, rs4737616	750 kb

* LD pattern is calculated in European population

The genetic variations listed in **Table 13** are the correspondent proxy SNP for each core or candidate SNP mentioned above derived from an exemplary genetic map concerning genetic data of the European population. The information derived by HapMap Project give us the best coverage of proxy SNPs in European population. Additional sources of information for genetic variation in linkage disequilibrium for European population and/or other populations can be retrieved through sources identifiable by a skilled person, which include for example Illumina BeadChip 1Million genotype data on our population. When referring to sources such as HapMap a continuous updating with respect of the source release is needed to ensure complete listing of all the relevant genetic variation in the sense of the present disclosure.

Example 8: Sequence information concerning core SNPs and additional SNPs affecting response to rostafuroxin

In some embodiments of the present disclosure therapy can be evaluated based on detection of sequence information for several genetic variations affecting the

individual response to rostafuroxin. Sequence information concerning the core SNPs and related selected genotypes are reported in **Tables 14 and 15**.

Table 14: sequence information core SNPs

rsID	Sequence	Nucleotide variation	SEQ ID NO	Selected nucleotide variation	SEQ ID NO
rs1687 7182	TTTGAGAATACCAAATACAGAAAA TTCAATCAAATTTTAAAGTTGGTANTA ATTATACTTGTTATTGGAATGTAATTT AGTTTTCTTAATTTAGTTTCT	N= A, C, G, T	1	N= C or T	2
rs5013 093	GGAAAACCCAGTGCCCTCCCCTCC TCTCAAGCCTGGCCAGCTCTGACAG N GGGAGGACTCCCCAAAGAGA GGCTCTGGCCCTGGCTCCATGTCCT TCCAG	N= A, C, G, T	3	N= C or T	4
rs2461 911	GTCCAAATGTAATGTTCTAACTTAGTA CATTTGGAAAATTCTTTCCTAACNCCT CTGGGAAAACACAAAATATTACTTAC AAAATAAATGCATAAAAATG	N= A, C, G, T	5	N= G or A	6
rs1251 3375	GCTCGCCTTGGTCCACTGTGACACA CAGGCTGCTTTGCTGGGAAAGTTCTN CCTGACTCACTGGGGCTGCATGAAG CCTGGGGAGGCAAGCTTCTGGCGTG	N= A, C, G, T	7	N= G or T	8
rs1689 3522	TGACACATGTGGCAGTCTGAAAAGTT CTTATTGAGCCAGACTGTAGAGTTCT TGGAATCNCATACCATCTTCATGGG AATTATGATTCTACTCAGGCTGGGAG GAGTACATTAAGTGAAG	N= A, C, G, T	9	N= A or G	10
rs2345 088	CAACATTTGGATTATGGCATTGTTGGGA TTCTGATTTTCAGAATTATGATTGGCA ATTTAANTAATTCTGGCTCGGTATAT TAATAATGCAATGCTTTTTTCAAGCTA TTTGTAAGTGATTC	N= A, C, G, T	11	N= C or T	12

5

Table 15: sequence information selected genotypes core SNPs

rsID	Sequence	Selected nucleotide variation major allele	SEQ ID NO	Selected nucleotide variation minor allele	SEQ ID NO
rs1687 7182	TTTGAGAATACCAAATACAGAAAA TTCAATCAAATTTTAAAGTTGGTANTA ATTATACTTGTTATTGGAATGTAATTT AGTTTTCTTAATTTAGTTTCT	N=C	13	N=T	14

Table 15: sequence information selected genotypes core SNPs

rsID	Sequence	Selected nucleotide variation major allele	SEQ ID NO	Selected nucleotide variation minor allele	SEQ ID NO
rs5013093	GGAAAACCCAGTGCCCTCCCCTCC TCTCAAGCCTGGCCAGCTCTGACAG NGGGAGGACTCCCCAAAGAGAGGCT CTGGCCCTGGCTCCATGTCCTTCCA G	N=T	15	N=T	16
rs2461911	GTCCAAATGTAATGTTCTAACTTAGTA CATTGGAAAATTCTTTCCTAACNCCT CTGGGAAAACACAAAATATTACTTAC AAAATAAATGCATAAAAATG	N= A	17	N= A	18
rs12513375	GCTCGCCTTGGTCCACTGTGACACA CAGGCTGCTTTGCTGGGAAAGTTCTN CCTGACTCACTGGGGCTGCATGAAG CCTGGGGAGGCAAGCTTCTGGCGTG	N= T	19	N= T	20
rs16893522	TGACACATGTGGCAGTCTGAAAAGTT CTTATTGAGCCAGACTGTAGAGTTCT TGAAATCNCATACCATCTTCATGGG AATTATGATTCTACTCAGGCTGGGAG GAGTACATTAAGTGAAG	N= A	21	N= A	22
rs2345088	CAACATTTGGATTATGGCATTGGGA TTCTGATTTTCAGAATTATGATTGGCA ATTTAANTAATTCTGGCTCGGTATAT TAATAATGCAATGCTTTTTTCAAGCTA TTTGTAAGTGATTC	N= T	23	N= T	24

Sequence information for exemplary additional SNPs affecting the response to rostafuroxin, and related selected genotypes is reported in **Table 16 and 17**.

Table 16: sequence information of additional SNPs affecting response

rsID	Sequence	Nucleotide variation	SEQ ID NO	Selected nucleotide variation	SEQ ID NO
Rs 4961	AGAAGACAAGATGGCTGAACTCT GGCCGGGGCGACGAAGCTTCCG AGGAANGGCAGAATGGAAGCAGT CCAAGTCGAAGACTAAGGTGTG GACGAACATT	N= A, C, G, T	25	N=G or T	26
Rs 4984	CTTCATCAAACACACCTAC CAATATGTTACTCCAGATGT GGAGGGCAACNCTGAAGAACTC GCACACGGCCGGACCAGAGCCT GGCTCTCGTTCCTGTCC	N= A, C, G, T	27	N= G or A	28

Table 16: sequence information of additional SNPs affecting response

rsID	Sequence	Nucleotide variation	SEQ ID NO	Selected nucleotide variation	SEQ ID NO
Rs 10923835	CTACAAGTCTTTTATGCTCTGAAG CTTTTGTCTTGGCAATTGCTTTA CANCATTCACAAAGGACAGCATT TACCTGGAGACCTCACCAGTGGG TCCCTGC	N= A, C, G, T	29	N= A or T	30
Rs 947130	TCTGAACAATTTGGGATCTCTTTT AACTTGAGGGTCTCTTTCGACTA CTANAGCTCCATTTCCCCTCTTAA ATGAGAAGGG ATTTCTTTTCTTTTAAATCT	N= A, C, G, T	31	N= C or T	32
Rs 914247	GCCAGGGACTGCTACCTGCCCA GAAGGCGGCAGGGAGGGGAAGA GCAGATNAGGAGGTATAGGGTGT GCCCTGGGCAAGGCAGCAGGGG TAACGAAGCTCT	N= A, C, G, T	33	N= A or G	34
Rs 1045642	GAGAACATTGCCTATGGAGACAA CAGCCGGGTGGTGTACAGGAA GAGATNGTGAGGGCAGCAAAGG AGCCAACATACATGCCTTCATC GAGTCACTGCC	N= A, C, G, T	35	N= C or T	36
Rs 880054	ACAGTAATAGTCTATTTAGCCTCT TTCTCTCCTGCTCTCCTTTCCATA TTNTTATGTGGCATATTA ACTTAA CACTAATGT ATGCAGGGTTTTGTTGGTTT	N= A, C, G, T	37	N= C or T	38
Rs 10502933	AATGTGATTTTTGATATAATTCTC ATGTTTTAGCTTTTCTAGTTTAAAA ANCTGCATACTGGAAAATAAGGA AAAAATTCTAGAGGTTGTATGAGA AGGA	N= A, C, G, T	39	N= C or T	40
Rs 2131127	AACCAACTTTAGCATAACCAAGTTT AGCATTTAGGCATAACCAACTTTAG CANTGTTATACAGAATAATGTTAG CATTGGAAGGATCTATTAACAAAA GAAAG	N= A, C, G, T	41	N= C or T	42
Rs 4309483	CCTCATGCAAAGCACTTGCTCAC ACACTGTCTCATTTC AACATCACC GCCNCTTAAGGAGATGCTATGAT CAACCCCACTTTGCAGATGAGGA AACTTCAG	N= A, C, G, T	43	N= C or A	44
Rs 4739037	CTGGAGCTCGCCTTACACCAAAC AGACACAATCGATCCATT CGAAG TGTCNTAATTACACATTGAGGGA CCA ACTAGACCTTTTCTCATTGTA AACTTGGA	N= A, C, G, T	45	N= G or A	46

Table 17: sequence information of selected genotypes of additional SNPs affecting response

rsID	Sequence	Selected nucleotide variation major allele	SEQ ID NO	Selected nucleotide variation minor allele	SEQ ID NO
Rs 4961	AGAAGACAAGATGGCTGAACTCT GGCCGGGGCGACGAAGCTTCCG AGGAANGGCAGAATGGAAGCAGT CCCAAGTCGAAGACTAAGGTGTG GACGAACATT	N= G or T	47	N=T	48
Rs 4984	CTTCATCAAAACACACCTAC CAATATGTTACTCCAGATGT GGAGGGCAACNCTGAAGAACTC GCACACGGCCGGACCAGAGCCT GGCTCTCGTTCCTGTCC	N=C	49	N=C	50
Rs 10923835	CTACAAGTCTTTTATGCTCTGAAG CTTTTTGTCTTGGCAATTGCTTTA CANCATTCACAAAGGACAGCATT TACCTGGAGACCTCACCAGTGGG TCCCTGC	N=A or T	51	N=T	52
Rs 947130	TCTGAACAATTTGGGATCTCTTTT AACTTGAGGGTCTCTTTCGACTA CTANAGCTCCATTTCCCCTCTTAA ATGAGAAGGG ATTTCTTTTCTTTTAAATCT	N=G	53	N=G	54
Rs 914247	GCCAGGGACTGCTACCTGCCCA GAAGGCGGCAGGGAGGGGAAGA GCAGATNAGGAGGTATAGGGTGT GCCCTGGGCAAGGCAGCAGGGG TAACGAAGCTCT	N=A	55	N=A	56
Rs 1045642	GAGAACATTGCCTATGGAGACAA CAGCCGGGTGGTGTACAGGAA GAGATNGTGAGGGCAGCAAAGG AGGCCAACATACATGCCTTCATC GAGTCACTGCC	N=T	57	N=T	58
Rs 880054	ACAGTAATAGTCTATTTAGCCTCT TTCTCTCCTGCTCTCCTTTCCATA TTNTTATGTGGCATATTA ACTTAA CACTAATGT ATGCAGGGTTTTGTTGGTTT	N= A or G	59	N=G	60
Rs 10502933	AATGTGATTTTTGATATAATTCTC ATGTTTTAGCTTTTCTAGTTTAAAA ANCTGCATACTGGAAAATAAGGA AAAAATTCTAGAGGTTGTATGAGA AGGA	N=C	61	N=T	62
Rs 2131127	AACCAACTTTAGCATAACCAAGTTT AGCATTTAGGCATAACCAACTTTAG CANTGTTATACAGAATAATGTTAG CATTGGAAGGATCTATTAACAAAA GAAAG	N=C	63	N=C	64

Table 17: sequence information of selected genotypes of additional SNPs affecting response

rsID	Sequence	Selected nucleotide variation major allele	SEQ ID NO	Selected nucleotide variation minor allele	SEQ ID NO
Rs 4309483	CCTCATGCAAAGCACTTGCTCAC A CACTGTCTCATTTC AACATCACC GCCNCTTAAGGAGATGCTATGAT CAACCCCACTTTGCAGATGAGGA AACTTCAG	N=A	65	N=A	66
Rs 4739037	CTGGAGCTCGCCTTACACCAAAC A AGACACAATCGATCCATTGGAAG TGTCNTAATTACACATTGAGGGA CCA ACTAGACCTTTTCTCATTGTA AACTTGGA	N=G	67	N=A	68

Exemplary probes suitable to be used to detect sequence information in methods and systems herein described are listed in **Table 18**.

Table 18: exemplary probes for core SNPs

rsID	Primer forward	SEQ ID NO	Primer reverse	SEQ ID NO
rs16877182	TTTGAGAATACCAAATACAGAAA ATTCAATCAAATTTTAAAGTTGGTA	69	ATTAATATGAACAATAAC CTTATCATTAAATCAAAA GAATTAATCAAAGA	70
	TAATTATACTTGTTATTGGAATGTA ATTTAGTTTTCTTAATTTAGTTTCT	71	AAACTCTTATGGTTTTAT GACTCTTTTATTGTTAGT TTAAAATTTCAACCAT	72
rs5013093	GGAAAACCCAGTGCCCTCCCCTC CTCTCAAGCCTGGCCAGCTCTGAC AG	73	CCCTCCTGAGGGGTTTT CTCTCCGAGACCGGGA CCGAGGTACAGGAAGG TC	74
	GGGAGGACTCCCCAAAGAGA GGCTCTGGCCCTGGCTCCATGTC CTTCCAG	75	CCTTTTTGGGTCACGGG AGGGGAGGAGAGTTTCG GACCGGTCGAGACTGTC	76
rs2461911	GTCCAAATGTAATGTTCTAACTTAG TACATTTGGAAAATTCTTTCCTAAC	77	GGAGACCCTTTTGTGTT TTATAATGAATGTTTTTA TTTACGTATTTTAC	78
	CCTCTGGGAAAACACAAAATATTA CTTACAAAATAAATGCATAAAAAT G	79	CAGGTTTACATTACAAG ATTGAATCATGTAAACCT TTAAGAAAGGATTG	80
rs12513375	GCTCGCCTTGGTCCACTGTGACAC ACAGGCTGCTTTGCTGGGAAAGTT CT	81	GGACTGAGTGACCCCG ACGTA CTTCGGACCCCT CCGTT CGAAGACCGCAC	82

Table 18: exemplary probes for core SNPs

rsID	Primer forward	SEQ ID NO	Primer reverse	SEQ ID NO
	CCTGACTCACTGGGGCTGCATGAA GCCTGGGGAGGCAAGCTTCTGGC GTG	83	CGAGCGGAACCAGGTG ACACTGTGTGTCCGACG AAACGACCCTTTCAAGA	84
rs1689 3522	TGACACATGTGGCAGTCTGAAAAG TTCTTATTGAGCCAGACTGTAGAG TTCTTGGAATC	85	GTATGGTAAAGTACCCT TAATACTAAGATGAGTC CGACCCTCCTCATGTAA TTGTCTTC	86
	CATACCATCTTCATGGGAATTATG ATTCTACTCAGGCTGGGAGGAGTA CATTAACTGAAG	87	ACTGTGTACACCGTCAG ACTTTTCAAGAATAACTC GGTCTGACATCTCAAGA ACCTTTAG	88
rs2345 088	CAACATTTGGATTATGGCATTGG GATTCTGATTTTCAGAATTATGATT GGCAATTTTAA	89	ATTAAGACCGAGCCATA TAATTATTACGTTACGAA AAAAGTTCGATAAACATT CACTAAG	90
	TAATTCTGGCTCGGTATATTAATAA TGCAATGCTTTTTTCAAGCTATTTG TAAGTGATTC	91	GTTGTAAACCTAATACC GTAAACCCTAAGACTAA AAGTCTTAATACTAACC GTTAAAATT	92

Some of the methods and systems herein exemplified can overcome certain limitations of a non pharmacogenomic therapeutic use of rosfuroxin by proposing: the selection of a subset of patients according to their genetic characteristics (SNPs). In particular, the SNPs at issue appears to underlay the

5 blood pressure response to rosfuroxin (Core SNPs) alone and in combination with other SNPs (CAND 1, CAND 2) that are involved in mechanisms leading to hypertension and organ complications and that are also hit by rosfuroxin.

In particular, both the core SNPs and CAND 1 or CAND 2 SNPs contribute to the two phenotypes of interest: a) response to the selective drug b) development of

10 hypertension and its organ complications. Moreover, from the practical view point both groups of SNPs contribute to discriminate, between responders and not responders.

This finding can have two important implications in the quest to find the right drug for the right patient and to open a new line of research aimed at applying the network concept of a disease (so far studied in animal model) to human patients.

The results of studies on polygenic-multifactorial diseases in animal models suggest that the current paradigm: “one genetic molecular alteration (or one gene variant or SNP) “one pathophysiological mechanism”, and “one clinical symptom or disease”, should be abandoned in favor of a more broad concept of genetic environmental network of mechanisms. Disease may arise from a perturbation of this network. This perturbation may then be the target for a novel “causal” therapy.

10 This new concept under development in animal models is not readily applicable to humans because the unavailability or the specific tissues or organs whose abnormalities may trigger the disease of interest.

Methods herein described apply, for the first time, this strategy to humans. In fact, the combination of the genetic perturbation (defined by the two groups of SNPs) with the functional perturbation (measured as the blood pressure response to the very potent and selective antihypertensive agent, rostafuroxin) realizes a new approach to the identification of a peculiar genetic network underlying hypertension with its organ complications in a clinically relevant subset of patients (about 25%), that is 20 million people in Europe only.

20 In several embodiments, methods and systems herein described deal with the genetic heterogeneity of the individual patient in a profile and with epistasis of a gene of interest. Genetic heterogeneity and epistasis are the two major problems

to overcome for demonstrating causality of a given genetic mechanism in polygenic multifactorial diseases. The term genetic heterogeneity indicates that the same phenotype (biochemical, physiological or symptoms) may be produced by different genetic mechanisms. The term epistasis indicates that the effect of the same gene variant may be modulated (either blunted or magnified) by another variant arising from gene far away from the gene of interest.

These two well accepted genetic phenomena are hampering all the attempts to apply genetics to study the mechanisms underlying the human diseases or the response to therapy.

For instance, if one postulates that a given hormone (in the specific ouabain) or protein (in the specific adducin) are involved in causing a disease (in the specific hypertension) one has to admit that the genetic pathways involved in the synthesis, transport or excretion of the hormone are also involved in determining its critical tissue level and its biological effect.

Analogously, all the genes coding for the proteins involved in modulating the cellular function of that particular protein should be considered. Of course, each of these biochemical pathways may be differently affected by the genetic background of the individual patient.

In several embodiments, in methods and systems herein described the common findings linking the various SNPs of the profile are: a) the SNPs capacity to be associated to the blood pressure response to rosfuroxin that (core SNPs); and b) the SNPs ability affect the activity of rosfuroxin in preclinical studies and to be

associated to biochemical pathways underlying hypertension and its organ complications (CAND 1 and CAND 2 SNPs). Practical advantages of several embodiments of methods and systems herein described over the current antihypertensive therapy include a faster achievement of blood pressure control (through the reduction of trial and error period) in 25% of patients, 85% probability to classify responders and non responders against 30-40% of the current strategy and a good tolerability and quality of life in the treated individual as demonstrated by trial results for rostafuroxin and, most importantly, by the much wider interval of rostafuroxin doses between the active doses and the NOAEL(non adverse events levels) doses in animals (at least 100.000 time with rostafuroxin but only 20-50 time with the available drug). Additionally, in several embodiments of methods and systems herein described can be associated with a foreseeable efficient prevention of organ complication since the identity between the mechanisms affected by rostafuroxin and that underlying organ damage in the subset of patients selected by some methods and systems herein described.

This foreseeable increased efficiency has 3 clear implications over the current strategy: a) provide stronger rational (or arguments) to convince patients to follow the treatment for hypertension that is just a risk factor, but not a disease causing disturbing clinical symptoms, b) reduce the burden for patients experiencing a cardiovascular complication that contrarily, to hypertension per se, can produce a high degree of disability. c) Reduce health care costs because antihypertensive therapy may be focused on the subset of patients at greater risk to develop

cardiovascular and renal complications, which are the most important source of health costs.

Finally in the subset of patients selected with the profile 4 the magnitude of the blood pressure drop obtained with rostaduroxin is about 40% larger than that
5 obtained with the HCTZ or Losartan. This difference is much larger than that so far detected among the various antihypertensive drugs.

In general, the methods and systems herein described allow, in several embodiments, an improvement in therapy of cardiovascular condition such as hypertension. At present, only 30-40% of never treated hypertensive patients
10 respond to the therapy with a clinically manfully fall in blood pressure. This generates frustration in the physicians, requires multiple changes of the therapy, and reduces the patients' compliance. As consequence, most patients are not adequately treated and this limits the prevention of the organ complications associated to high blood pressure. The methods and systems herein described
15 allow to correctly classifying as responders to the rostaduroxin therapy up to 85% of the patients, thus reducing the burden of finding an active treatment. A first improvement of several embodiments, concerns safety: the effective dose of rostaduroxin in the selected patients is very low and it may range from 50 to 500 $\mu\text{g}/\text{day}$. The effective doses in relevant animal models are from 0.1 to 100 $\mu\text{g}/\text{kg}$
20 while the maximal tolerated dose that does not produce any effects in animals (NOAEL) is of 100 mg/kg. This means that the interval between the active and the maximal tolerated dose of rostaduroxin in animals is higher than 100.000 times as

compared with the available antihypertensive therapies for which this interval ranges from 20 to 50 times. Some data concerning the efficacy and safety of new antihypertensive therapies and in particular of traditional therapeutic approaches compared with pharmacogenomic approaches is reported in **Figure 10**.

5 In summary, the methods and systems herein described (genotyping + rostafuroxin) combine a high safety with the more accurate prediction of the antihypertensive activity thus anticipating a high degree of prevention of the cardiovascular complications whose mechanisms are hinted by rostafuroxin.

Even though the precise mechanisms of the increased blood pressure drop after
10 rostafuroxin in individuals carrying at least one of the selected core SNPs are not known, they are expected to be related to the mechanisms triggered by the molecular targets hit by rostafuroxin. As consequence, benefits beyond those related to the blood pressure drop induced by rostafuroxin are expected in individuals carrying the core SNPs genotypes included in the profiles.

15 The examples set forth above are provided to give those of ordinary skill in the art a complete disclosure and description of how to make and use the embodiments of the methods and systems of the disclosure, and are not intended to limit the scope of what the inventors regard as their disclosure. Modifications of the above-described modes for carrying out the disclosure that are obvious to persons of skill
20 in the art are intended to be within the scope of the following claims. All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the disclosure pertains. All references cited in this

disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background, Summary, Detailed Description, and Examples is hereby incorporated herein by reference.

It is to be understood that the disclosures are not limited to particular compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. The term "plurality" includes two or more referents unless the content clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains.

Various methods and materials similar or equivalent to those described herein can be used in practice for testing the specific examples of appropriate materials and methods described herein and are identifiable by a skilled person.

A number of embodiments of the disclosure have been described. Nevertheless, it will be understood that various modifications may be made without departing from

the spirit and scope of the present disclosure. Accordingly, other embodiments are within the scope of the following claims.

REFERENCES

- [1] Ferrari P, Ferrandi M, Tripodi G, Torielli L, Padoani G, Minotti E. PST 2238: a
5 new antihypertensive compound that modulates Na,K-ATPase in genetic
hypertension, *J. Pharmacol. Exp. Ther.*, 1999; 288:1074 -1083.
- [2] Ferrari P, Ferrandi M, Valentini G, Bianchi G. Rostafuroxin: an ouabain
antagonist that corrects renal and vascular Na⁺-K⁺-ATPase alterations in
ouabain and adducin-dependent hypertension. *Am J Physiol. Regul Integr*
10 *Comp Physiol* 2006; 290:529 -535.
- [3] Ferrari P, Ferrandi M, Torielli L, Tripodi G, Melloni P, Bianchi G. PST 2238: a
new antihypertensive compound that modulates Na⁺,K⁺-ATPase and
antagonizes the pressor effect of OLF. *Cardiovasc Drug Rev* 1999; 17:39-57.).
- [4] Bianchi G. et al., *Pharmacogenomics* 2003 May; 4(3):279-96.
- 15 [5] *J. Med. Chem.*, 1997; 40(11); 1561-1564.
- [6] Ferrari P et al. *JPET* 1998; 285: 83-94.
- [7] 2003 European Society of Hypertension-European Society of Cardiology
guidelines for the management of arterial hypertension. Guidelines Committee
Journal of Hypertension. 21(6):1011-1053, June 2003.
- 20 [8] O'Brien, Eoin; Asmar, Roland; Beilin, Lawrie; Imai, Yutaka; Mallion, Jean-
Michel; Mancia, Giuseppe; Mengden, Thomas; Myers, Martin; Padfield, Paul;
Palatini, Paolo; Parati, Gianfranco; Pickering, Thomas; Redon, Josep;

- Staessen, Jan; Stergiou, George; Verdecchia, Paolo on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. *Journal of Hypertension*. 21(5):821-848, May 2003.
- 5
- [9] Sambrook J, Russell DW. *Molecular cloning, A laboratory manual*. (Chapter 6). Cold Spring Harbor Laboratory Press 2001.
- [10] Steemers FJ, Gunderson KL. *Illumina Inc. Pharmacogenomics* 2005; 6:777-782.
- 10 [11] Phase I HapMap, 2005. The international HapMap Consortium. *A Haplotype Map of The Human Genome* 2005; 437:1299-1320.
- [12] Phase II HapMap, 2007. The international HapMap Consortium, *A second generation human haplotype map of over 3.1 million SNPs*. *Nature* 2007; 449:851-861.
- 15 [13] Report Valentini.
- [14] Page IH, Dustan HP. *Persistence of normal blood pressure after discontinuing treatment in hypertensive patients*. *Circulation* 1962; 25:433-436.
- [15] Fletcher AE, Franks PJ, Bulpitt CJ. *The effect of withdrawing antihypertensive therapy: a review*. *J Hypertens* 1988; 6:431-436.
- 20 [16] Veterans Administration Cooperative Study Group on Antihypertensive Agents. *Return of elevated blood pressure after withdrawal of antihypertensive drugs*. *Circulation* 1975; 51:1107-1113.

- [17] Levinson PD, Khatri Im, Freis ED. Persistence of normal blood pressure after withdrawal of drug treatment in mild hypertension. Arch Int Med 1982; 142:2265-2268.
- [18] Nelson MR, Reid CM, Krum H, Ryan P, Wing LMH, McNeil JJ. Short-term
5 predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the second Australian national blood pressure study (ANBP2). American Journal Hypertens 2003; 16:39-45.
- [19] Takata Y, Yoshizumi T, Ito Y, Ueno M, Tsukashima A, Iwase M et al.
10 Comparison of withdrawing antihypertensive therapy between diuretics and angiotensin converting enzyme inhibitors in essential hypertensives. American Heart Journal 1992; 124:1574-1580.
- [20] Blafox MD, Langford HG, Oberman A, Hawkins CM, Wassertheil-Smoller S, Cutter GR. Effect of dietary change on the return of hypertension after withdrawal of prolonged antihypertensive therapy (DISH). J Hypertens 1984;
15 2(suppl 3):179-181.
- [21] Ho GYF, Blafox MD, Wassertheil-Smoller S, Oberman A, Langford HG. Plasma renin predicts success of antihypertensive drug withdrawal. American Journal Hypertens 1994; 7:679-684.
- [22] Swart S, Bing RF, Swales JD, Thurston H. Plasma renin in long-term diuretic
20 treatment of hypertension: effect of discontinuation and restarting therapy. Clin Sci 1982; 63:121-125.

- [23] Fagerberg B, Wikstrand J, Berglund G, Hartford M, Ljungman S, Wendelhag I. Withdrawal of antihypertensive drug treatment: time-course for redevelopment of hypertension and effects upon left ventricular mass. *J Hypertens* 1992; 10:587-593.
- 5 [24] Zanchetti A, Mancia G. The dilemma of placebo controlled studies: scientific evidence, guidelines, ethics and regulatory recommendations. *J Hypertens* 2009; 27:1-2.
- [25] Farquharson CAJ, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril
10 therapy in chronic heart failure. *J Am Coll Cardiol* 2002; 39:767-775.
- [26] Chevillard C, Brown NL, Jouquey S, Mathieu MN, Lalibertè F, Hamon G. Cardiovascular actions and tissue-converting enzyme inhibitory effects of chronic enalapril and trandolapril treatment of spontaneously hypertensive rats. *J Cardiovasc Pharamcol* 1989; 14:297-301.
- 15 [27] Unger T, Ganten D, Lang RE, Schölkens A. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats. *J Cardiovasc Pharmacol* 1985; 7:36-41.
- [28] Paull JRA, Widdop RE. Persistent cardiovascular effects of chronic renin-
20 angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. *J Hypertens* 2001; 19:1393-1402.

- [29] Guerrero EI, Ardanaz N, Sevilla MA, Arèvalo MA, Montero MJ. Cardiovascular effects of nebivolol in spontaneously hypertensive rats persist after treatment withdrawal. *J Hypertens* 2006; 24:151-158.
- [30] Dukacz SAW, Adams MA, Kline RL. The persistent effect of long-term enalapril on pressure natriuresis in spontaneously hypertensive rats. *Am J Physiol Renal Physiol* 1997; 273 o 42:F104-F112.
- [31] Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. *Am J Hum Genet.* 2005; 76:887-893.
- [32] Devlin B, Bacanu B, Roeder K: Genomic Control in the Extreme. *Nature Genetics* 2004; 36:1129-1130.
- [33] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D. A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *Am. J. Hum Gen* 2007; 81:559–575.
- [34] The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007; 447:661-678.
- [35] Potkin S, Turner J, Guffanti G, Lakatos A, Torri F, Keator DB, Macciardi F. Genome-wide Strategies for Discovering Genetic Influences on Cognition and Cognitive Disorders: Methodological Consideration. Submitted to *Cognitive Psychiatry Cogn Neuropsychiatry*. 2009;14(4-5):391-418
- [36] Agresti A. 1984. *Analysis of Ordinal Categorical Data* - New York: John Wiley & Sons, Inc.

- [37] Resson HW, Varghese RS, Zhang Z, Xuan J, Clarke R. Classification algorithms for phenotype prediction in genomics and proteomics. *Front Biosci.* 2008; 1;13:691-708.
- [38] Guidance for Industry: Pharmacogenomics data submission; FDA report, 5 March 2005; <http://www.fda.gov/cder/guidance/index.htm>).
- [39] Phillips PC. Epistasis the essential role of gene interactions in the structure and evolution of genetic systems. *Nar Rev Genet* 2008; 9:855-867.
- [40] Pheasant M, Mattick JS. Raising the estimate of functional human sequences. *Genome Res.* 2007 Sep;17(9):1245-53.

CLAIMS

1. Rostafuroxin for use in treatment or prevention of a cardiovascular condition in an individual

5

wherein said individual has been selected to be a carrier of at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375 and/or of a genetic variation in linkage disequilibrium therewith.

10

2. The rostafuroxin of claim 1, wherein the at least one polymorphism is selected from the group consisting of nucleotide C or T for rs2345088, nucleotide C or T for rs16877182, nucleotide G or A for rs16893522, nucleotide G or A for rs2461911, nucleotide C or T for rs5013093, and nucleotide T or G for rs12513375.

15

3. The rostafuroxin of claim 1 or 2, wherein the individual has been selected to be a carrier of at least one genotype selected from the group consisting of genotype TT or genotype 1 for rs2345088, genotype C/T or genotype 2 for rs16877182, genotype AA or genotype 1 for rs16893522, genotype AA or genotype 1 for rs2461911, genotype TT or genotype 1 for rs5013093, and genotype TT or genotype 1 for rs12513375.

20

4. The rostafuroxin of anyone of claims 1 to 3, wherein the individual has been selected to be a carrier of a polymorphism in at least one CAND 1 gene, CAND 2 gene and/or GWS gene.
- 5 5. The rostafuroxin of claim 4, wherein the individual has been selected to be a carrier also of at least one polymorphism in at least one gene selected from the group consisting of ADD1, ADD2, ADD3, CYP11A1, HSD3B1, LSS, ABCB/MDR1, and SLCO4C1.
- 10 6. The rostafuroxin of anyone of claims 1 to 5, wherein the individual has been selected to be a carrier of at least one single nucleotide polymorphisms selected from the group consisting of rs4961, rs4984, rs3731566, rs914247, and rs1045642 and/or of a genetic variation in linkage disequilibrium therewith.
- 15 7. The rostafuroxin of anyone of claims 1 to 6, wherein the individual has been selected to be a carrier of at least one genotype selected from the group consisting of GT for rs4961, CT for rs4984, AG for rs3731566, GA for rs914247, and TC for rs1045642.
- 20 8. The rostafuroxin of anyone of claims 1 to 7, wherein the individual has been selected to be a carrier of genotype AA for rs914247.

9. The rostafuroxin of anyone of claims 1 to 8, wherein the individual has been selected to be a carrier of at least one single nucleotide polymorphism selected from the group consisting of rs242093, rs1996396, rs10503806, rs13251780, rs17430706, rs10102024, rs526302, rs544104, rs3102087, rs5183, rs3772627, 5 rs2276736, rs2131127, rs3741559, rs2217342, rs10927888, rs6604909, rs945403, rs7117314, rs10790212, rs11216598, rs910682, rs13218316, rs4309483, rs13280307, rs4739037, rs17596774, rs2728108, rs17786456, rs7696304, rs2725222, rs17199565, rs2758152, rs1057293, rs16960712, rs759359, rs404214, rs1005213, rs17025453, rs2110923, rs1428571, rs435404, rs12908787, 10 rs11647727, rs880054, and rs11064584 and/or of a genetic variation in linkage disequilibrium therewith.

10. The rostafuroxin of anyone of claims 1 to 9, wherein the individual has been selected to be a carrier of at least one single nucleotide polymorphism selected 15 from the group consisting of rs12996186, rs9893372, rs7216331, rs7521668, rs188334, rs4998662, rs16893522, rs6457110, rs3893464, rs2517718, rs1362126, rs5013093, rs2345088, rs6718282, rs721207, rs2555500, rs2461911, rs8179654, rs1901139, rs2427832, rs9361863, rs1998394, ga001619, rs2275531, rs748140, rs4710592, rs2743951, rs10159569, rs3087816, rs10493940, rs16877182, 20 rs2326912, rs1110446, rs12513375, and rs17414954 and/or of a genetic variation in linkage disequilibrium therewith.

11. The rostafuroxin of anyone of claims 1 to 10, wherein the individual has been selected to a carrier of at least one single nucleotide polymorphism selected from the group consisting of rs4961, rs4984, rs10923835, rs947130, rs914247, rs1045642, rs880054, rs10502933, rs2131127, rs4309483, and rs4739037.

5

12. The rostafuroxin of anyone of claims 1 to 10, wherein the individual has been selected to a carrier of at least one single nucleotide polymorphism selected from the group consisting of rs1045642, rs10923835, rs914247, rs4961, rs947130, rs4309483, rs2131127, rs10502933, and rs880054 (profile 8).

10

13. The rostafuroxin of anyone of claims 1 to 10, wherein the individual has been selected to a carrier of at least one single nucleotide polymorphism selected from the group consisting of rs1045642, rs10923835, rs914247, rs947130, rs4739037, rs43909483, rs4984, rs10502933 rs880054 (profile 9).

15

14. The rostafuroxin of anyone of claims 1 to 13, where the cardiovascular condition is hypertension and/or a condition associated thereto.

20

15. The rostafuroxin of claim 14, wherein the cardiovascular condition is at least one of cardiac hypertrophy, cardiac insufficiency, cardiac failure, cardiac ischemia, increased vascular resistances, increased vascular reactivity, vascular stiffness, increased vascular thickness, renal hypertrophy, renal failure, glomerulosclerosis,

proteinuria, polycystic renal disease, retinal damage, cerebrovascular disorders, cerebrovascular damage, stroke, Meniere syndrome, cognitive disorders, bipolar disorders.

5 16. Rostafuroxin for use as a medicament, in a dosage of from 0.005 mg/day to 5 mg/day to be administered for treating an individual, wherein the individual has been selected to have a genotype comprising at least one of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375 and/or a genetic variation in linkage disequilibrium therewith.

10

17. The rostafuroxin of claim 16, wherein treatment with rostafuroxin is directed to elicit at least one biological activity selected from the group consisting of elective inhibition of the ouabain hypertensive effect, normalization of alterations in the Na-K pump and Src caused by ouabain, normalization in forms of hypertension
15 sustained by the concomitant increase of endogenous ouabain levels and alterations in the Na-K pump and Src.

18. The rostafuroxin of claim 16 or 17, wherein treatment with rostafuroxin is directed to elicit at least one biological activity selected from the group consisting of
20 selective antagonism of the hypertensive effect associated to the genetic variations of genes coding for adducin or other enzymes involved in synthesis and transport of endogenous ouabain, normalization of alterations in the Na-K pump and Src

caused by adducin genetic variations, and normalization in forms of hypertension sustained by the concomitant effects of adducin genetic variations and alterations in the Na-K pump and Src.

5 19. The rostaduroxin of anyone of claims 16 to 18, wherein the dosage is from 0.05 mg/day to 0.15 mg/day and wherein administering or prescribing rostaduroxin to the individual results in an average blood pressure decrease of about 23 mm Hg.

10 20. The rostaduroxin of anyone of claims 16 to 18, wherein the dosage is from 1.5 mg/day to 5.0 mg/day and wherein administering or prescribing rostaduroxin to the individual results in an average blood pressure decrease of about 15 mm Hg.

15 21. The rostaduroxin of anyone of claims 16 to 18, wherein the dosage is from 0.05 mg/day to 1.5 mg/day and wherein administration rostaduroxinto the individual results in an average decrease of nightly blood pressure.

20 22. The rostaduroxin of anyone of claims 16 to 18, wherein the individual has been selected to be a carrier also of a polymorphism in at least one CAND 1 gene, CAND 2 gene and/or GWS gene and wherein administering or prescribing rostaduroxin to the individual results in an average decrease ranging from about 8 to about 22.5 mmHg.

23. The rostafuroxin of claim 22, wherein the at least one CAND 1 gene is selected from the group consisting of ADD1, ADD2, ADD3, LSS, MDR1, HSD3B1, CYP11A1, and SLCO4C1.

5 24. The rostafuroxin of claim 22 or 23, wherein the at least one CAND 2 gene is selected from the group consisting of ACTN1, ADRA1A, AGTR1, AQP2, ATP1A3, CLCNKA, CLCNKB, FXYD2, FXYD6, FYN, NEDD4L, NKAIN3, PKD1, PKD2, SCNN1B, SGK1, SLC12A1, SLC8A1, TJP1, UMOD, and WNK1.

10 25. The rostafuroxin of anyone of claims 22 to 24, wherein the at least one GWS gene is selected from the group consisting of ARL5A, ATP2A3, COX10, DPH5, FAIM3, FAM46A, HCG9, HLA-A, HLA-F, HLA-G, KCNS3, LOC131691, LOC389174, LOC389970, LOC642727, LOC644192, LOC649458, LOC728360, LOC728316, PIGR, RCADH5, RP3-377H14.5, SH3PXD2A, SLC30A7, THSD7A,
15 TMEM200A, TRIM31, TTC29, and VCAM1.

26. The rostafuroxin of claim 23, wherein the at least one CAND 1 gene, CAND 2 gene and GWS gene is selected from the group consisting of MDSR 2, HSD18, LSS2, HSD19, ADD2, WNK.

27. The rostavuroxin of anyone of claims 22 to 26 wherein the polymorphism in at least one CAND 1 gene, CAND 2 gene and/or GWS gene is a single nucleotide polymorphism.

5 28. The rostavuroxin of anyone of claims 16 to 27, wherein the dosage is administered via oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, rectal means or locally on the diseased tissue after surgical operation.

10

29. A method for identifying an individual with improved response to rostavuroxin, the method comprising detecting in an isolated DNA sample of the individual a single nucleotide polymorphism in any one of the nucleotide sequences of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID
15 NO: 11, wherein the presence of the SNP is correlated with an improved response to rostavuroxin in said individual.

30. The method of claim 29, wherein the detected single nucleotide polymorphism is selected from the groups consisting of rs2345088, rs16877182, rs16893522,
20 rs2461911, rs5013093, and rs12513375.

31. An isolated nucleic acid molecule comprising at least one sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, and SEQ ID NO: 12, or a complement thereof.
- 5 32. An isolated nucleic acid molecule comprising at least one sequence selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46 or a complement thereof.
- 10 33. A system for detecting a single nucleotide polymorphism in a nucleic acid, the system comprising
- an isolated polynucleotide specifically hybridizing to a nucleic acid molecule containing a single nucleotide polymorphism in any one of the nucleotide sequences SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID
- 15 NO: 9 and SEQ ID NO:11;
- a buffer, and
- an enzyme suitable to be used in combination with the isolated polynucleotide to detect a single nucleotide polymorphism in the nucleic acid.
- 20 34. The system of claim 33, wherein the isolated polynucleotide comprises at least one sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4,

SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12 or a fragment thereof.

35. The system of claim 33 or 34, further comprising an isolated polynucleotide
5 specifically hybridizing to a nucleic acid molecule containing a single nucleotide polymorphism in any one of the nucleotide sequences SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43 and SEQ ID NO: 45.

10 36. The system of claim 35, wherein the isolated polynucleotide comprises at least one sequence selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46 or a fragment thereof.

15

37. A system for evaluating rostaduroxin treatment for an individual, the system comprising:

a probe for at least one polymorphism selected from the group consisting of rs2345088, rs16877182, rs16893522, rs2461911, rs5013093, and rs12513375,

20 and/or a genetic variation in linkage disequilibrium therewith; and

a pharmaceutical composition comprising rostavuroxin in a dosage of from 0.005 mg to 5 mg/day and in particular from 0.05 to 0.5 mg/day and a pharmaceutically acceptable vehicle.

5 38. The system of claim 37, wherein the probe comprises at least one isolated polynucleotide selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12 or a fragment thereof, the fragment capable of specifically hybridizing a sequence complementary to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8,
10 SEQ ID NO: 10 or SEQ ID NO: 12.

39. The system of claim 37 or 38, the system further comprising a probe for at least one polymorphism selected from the group consisting of rs4961, rs4984, rs10923835, rs947130, rs914247, rs1045642, rs880054, rs10502933, rs2131127,
15 rs4309483, and rs4739037.

40. The system of claim 39, wherein the probe comprises at least one isolated polynucleotide selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46 or a fragment thereof, the fragment capable of specifically hybridizing a sequence complementary to SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO:
20

32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44 or SEQ ID NO: 46.

41. The system of anyone of claims 37 to 40, wherein the probes have a sequence
5 selected from the group consisting of SEQ ID NO: 35 to SEQ ID NO: 58.

42. A system for detecting a single nucleotide polymorphism in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, the system comprising:

10 an isolated polynucleotide which specifically hybridizes to a nucleic acid molecule containing a single nucleotide polymorphism in any one of the nucleotide sequences SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID NO: 11;

a buffer; and

15 an enzyme suitable to be used in combination with the isolated polynucleotide to detect a single nucleotide polymorphism in the nucleic acid.

1/10




FIG. 1




FIG. 2

3/10




FIG. 3

4/10




FIG. 4

5/10






FIG. 5

1) ANOVA analysis of rs2461911 for placebo group:

Summary of DSBP50			
rs2461911	Mean	Std. Dev.	Freq.
1	2.2166667	10.168268	6
2	-6.7055556	11.987897	36
3	-9.4923076	10.596815	52
Total	-7.6776596	11.390603	94

2) ANOVA analysis of rs2461911 for therapy group:

Summary of DSBP50			
rs2461911	Mean	Std. Dev.	Freq.
1	-20.6	12.67024	5
2	-7.9238095	12.361344	42
3	-2.7211539	10.96131	52
Total	-5.8313131	12.294097	99

Analysis of Variance

Source	SS	df	MS	F	Prob >
Between groups	792.638933	2	396.319467		
3.20	0.0454				
Within groups	11273.7243	91	123.88708		
Total	12066.3632	93	129.745841		

Analysis of Variance

Source	SS	df	MS	F	Prob >
Between groups	1777.46998	2	888.734988		
6.55	0.0022				
Within groups	13034.7227	96	135.778362		
Total	14812.1927	98	151.144824		

FIG. 6

7/10




FIG. 7

	Profile 4	Profile 8	Profile 9
Response to treatments	rs16893522 rs5013093 rs2345088 rs2461911 rs16877182 rs12513375	Profile 4 MDR2- HSD18 LSS2- MDR2 LSS2- ADD1 HSD19-rs430948 MDR2- rs213112 ADD2- rs105029 LSS2-WNK	Profile 9 MDR2- HSD18 LSS2- MDR2 HSD19- rs473903 HSD19- rs430948 ADD2- rs105029 LSS2-WNK
pvalue	0.000	0.000	0.000
OddsRatio	14.64	32.62	69.75
sensitivity (se) %	54.5	82	82
PPV %	78.3	93	96
Correctly %	79.8	83	85
# true R	18/33	29/33	31/33
# true NR	61/66	54/66	54/66
DSBP5-0 Therapy (mmHg) mean ± SE (n)			
Treated with low doses	-18.74 ± 1.8	-15.2 ± 1.5	-15.2 ± 1.5
Treated with high doses	-23.12 ± 3.2 (10)	-17.9 ± 2.05 (22)	-18.0 ± 2.0 (22)
DSBP5-0 Placebo (mmHg) mean	-15.2 ± 3.0 (13)	-12.6 ± 2.4 (19)	-12.3 ± 2.2 (21)
Losartan	-1.14	-2.57	-2.64
HCTZ	-11.37	-11.63	-11.43
Patients with profile treated / placebo	-12.34	-11.36	-11.95
Patients with profile	23 / 28	41 / 43	43 / 44
Patients with profile (%)	51	84	87
Patients with profile (%) (196 patients)	26%	42.8%	44.4%

FIG. 8

9/10

N	Gene Symbol	Chr	Gene name
1	ACE1	17	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
2	ACE2	X	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2
3	ACTA1	1	actin, alpha 1, skeletal muscle
4	ACTA2	10	actin, alpha 2, smooth muscle, aorta
5	ACTN1	14	actinin, alpha 1
6	ADRA1A	8	adrenergic, alpha-1A-, receptor
7	ADRA2B	2	adrenergic, alpha-2B-, receptor
8	ADRB1	10	adrenergic, beta-1-, receptor
9	ADRB2	5	adrenergic, beta-2-, receptor
10	ADRB3	8	adrenergic, beta-3-, receptor
11	AGT	1	angiotensinogen
12	AGTR1	3	angiotensin II receptor, type 1
13	AGTR2	X	angiotensin II receptor, type 2
14	AQP2	12	aquaporin 2
15	ATP1A1	1	ATPase, Na+/K+ transporting, alpha 1 polypeptide
16	ATP1A2	1	ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide
17	ATP1A3	19	ATPase, Na+/K+ transporting, alpha 3 (+) polypeptide
18	ATP1A4	1	ATPase, Na+/K+ transporting, alpha 4 (+) polypeptide
19	ATP1B1	1	ATPase, Na+/K+ transporting, beta 1 polypeptide
20	ATP1B2	17	ATPase, Na+/K+ transporting, beta 2 polypeptide
21	ATP1B3	3	ATPase, Na+/K+ transporting, beta 3 polypeptide
22	ATP1B4	X	ATPase, Na+/K+ transporting, beta 4 polypeptide
23	BSND	1	Bartter syndrome, infantile, with sensorineural deafness
24	CLCNKA	1	chloride channel Ka
25	CLCNKB	1	chloride channel Kb
26	CLTA	12	clathrin, light chain (Lca)
27	CLTB	4	clathrin, light chain (Lcb)
28	CLTC	17	clathrin, heavy chain (Hc)
29	CLTCL1	22	clathrin, heavy polypeptide-like 1
30	CYP11B2	8	cytochrome P450, family 11, subfamily B, polypeptide 2
31	DRD1	5	dopamine receptor D1
32	DRD3	3	dopamine receptor D3
33	DRD4	11	dopamine receptor D4
34	DRD5	4	dopamine receptor D5
35	FXD1	19	FXD domain containing ion transport regulator 1
36	FXD2	11	FXD domain containing ion transport regulator 2
37	FXD3	19	FXD domain containing ion transport regulator 3
38	FXD4	10	FXD domain containing ion transport regulator 4
39	FXD5	19	FXD domain containing ion transport regulator 5
40	FXD6	11	FXD domain containing ion transport regulator 6
41	FXD7	19	FXD domain containing ion transport regulator 7
42	FXD8	X	FXD domain containing ion transport regulator 8
43	FYN	6	FYN oncogene related to SRC, FGR, YES [
44	GNB3	12	guanine nucleotide binding protein (G protein), beta polypeptide 3
45	KCNJ1	11	potassium inwardly-rectifying channel, subfamily J, member 1 (ROMK)
46	LYN	8	v-src-1 Yamaguchi sarcoma viral related oncogene homolog
47	NCL	2	nucleolin
48	NEDD4	15	neural precursor cell expressed, developmentally down-regulated 4
49	NEDD4L	18	neural precursor cell expressed, developmentally down-regulated 4-like
50	NKAIN1	1	Na+/K+ transporting ATPase interacting 1
51	NKAIN2	6	Na+/K+ transporting ATPase interacting 2
52	NKAIN3	8	Na+/K+ transporting ATPase interacting 3
53	NKAIN4	20	Na+/K+ transporting ATPase interacting 4
54	NOS3	7	nitric oxide synthase 3 (endothelial cell)
55	NPHS1	19	nephrosis 1, congenital, Finnish type (nephrin)
56	NPHS2	1	nephrosis 2, idiopathic, steroid-resistant (podocin)
57	PKD1	16	polycystic kidney disease 1 (autosomal dominant)
58	PKD2	4	polycystic kidney disease 2 (autosomal dominant)
59	REN	1	renin
60	RFX1	19	regulatory factor X, 1
61	RPH3A	12	rabphilin 3A homolog (mouse)
62	RPH3AL	17	rabphilin 3A-like (without C2 domains)
63	SCNN1A	12	sodium channel, nonvoltage-gated 1 alpha
64	SCNN1B	16	sodium channel, nonvoltage-gated 1, beta
65	SCNN1D	1	sodium channel, nonvoltage-gated 1, delta
66	SGK1	6	serum/glucocorticoid regulated kinase 1
67	SLC12A1	15	solute carrier family 12 (sodium/potassium/chloride transporters), member 1
68	SLC12A3	16	solute carrier family 12 (sodium/chloride transporters), member 3
69	SLC8A1	2	solute carrier family 8 (sodium/calcium exchanger), member 1
70	SYNPO	5	synaptopodin
71	SRC	20	v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)
72	TJP1	15	tight junction protein 1 (zona occludens 1)
73	UMOD	16	uromodulin
74	WNK1	12	WNK lysine deficient protein kinase 1
75	WNK4	17	WNK lysine deficient protein kinase 4

FIG. 9

10/10

**Efficacy and safety data for new Antihypertensive Therapies:
comparison between Traditional and Innovative Pharmacogenomic Approaches**

Parameter	Traditional	Pharmacogenomic (Rostafuroxin data)
<u>Antihypertensive Efficacy</u> (Δ Systolic BP mmHg, minus placebo)	-6 / -12	-14 / -23
<u>Superiority among Drug Classes</u> (Δ SBP, mmHg, in never treated patients)	0 / -3	-5 / -11
<u>Reduction of CV complications</u>	20-30%	not yet assessed, but expected to be superior *
<u>Safety ratio</u> (in preclinical models)	1:20 – 1:40	> 1: 10.000

n.b. The comparison between the traditional and new approach, considers similar treatment duration and basal BP levels of the patients.

* the improved prevention of CV complications is expected due to the better BP control and the selective targeting of the genetic alterations (gene profile) responsible for the CV complications.

FIG. 10